Document:

Amendment No. 5 to Acquisition Agreement

 EXHIBIT NO. 10.2 

AMENDMENT NO. 5 TO ACQUISITION AGREEMENT 
 THIS AMENDMENT NO. 5 TO ACQUISITION AGREEMENT (this “Amendment”) is entered into as of this 17th day of October, 2011, by and among Mattersight Corporation (f/k/a eLoyalty Corporation), a
Delaware corporation (“Seller”), TeleTech Holdings, Inc., a Delaware corporation (“Parent”), and eLoyalty, LLC (f/k/a Magellan Acquisition Sub, LLC), a Colorado limited liability company and a wholly-owned
subsidiary of Parent (“Buyer” and, together with Seller and Parent, the “Parties”). 

W I T N E S S E T H: 

WHEREAS, pursuant to that certain Acquisition Agreement, dated as of March 17, 2011, as amended by that certain Amendment No. 1
thereto, dated as of May 27, 2011, that certain Amendment No. 2 thereto, dated as of June 20, 2011, that certain Amendment No. 3 thereto, dated as of June 20, 2011, that certain Amendment No. 4 thereto, dated as of
September 7, 2011 (as may be further amended, modified or supplemented from time to time in accordance with the terms thereof, the “Agreement”), by and among the Parties, Buyer agreed to purchase substantially all of the assets
of Seller used in or related to the ICS Business; 
 WHEREAS, the Parties desire to amend the Agreement on the terms and
conditions set forth in this Amendment; and 
 WHEREAS, unless otherwise defined herein, each capitalized term used herein shall
have the meaning assigned thereto in the Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the respective
covenants and agreements set forth herein, and intending to be legally bound hereby, subject to the conditions and other terms herein set forth, the Parties hereby agree as follows: 

1. Amendment. The Agreement is hereby amended as follows: 

(a) Final Pre-Closing Services Amount Definition. The definition of “Final Pre-Closing Services Amount”
shall be amended by deleting the words “September 30, 2011” and replacing them with the words “October 14, 2011”. 
 (b) Pre-Closing Service Contract Definition. The definition of “Pre-Closing Service Contract” shall be amended by deleting the words “September 30, 2011” and replacing them with
the words “October 14, 2011”. 
 (c) September Pre-Closing Services Amount Statement
Definition. The definition of “September Pre-Closing Services Amount Statement” shall be deleted in its entirety. 
 (d) New Definitions. Section 1.1 shall be amended by adding the following definition, in alphabetical order: 

 “October Pre-Closing Services Amount Statement” means a statement setting
forth the portion of the Final Pre-Closing Services Amount recognized and collected during the period beginning on July 26, 2011 and ending on October 14, 2011. 

(e) Section 2.7(a) shall be amended by (A) deleting the words “as soon as practicable following
September 30, 2011, but in any event no later than October 15, 2011,” and replacing them with the words “as soon as practicable following October 14, 2011, but in any event no later than October 31, 2011,” and
(B) deleting the words “September Pre-Closing Services Amount Statement” and replacing them with the words “October Pre-Closing Services Amount Statement”. 

(f) Section 2.7(b) shall be amended by deleting the words “September Pre-Closing Services Amount
Statement” and replacing them with the words “October Pre-Closing Services Amount Statement”. 

(g) Section 2.7(c) shall be amended by deleting the words “September Pre-Closing Services Amount
Statement” and replacing them with the words “October Pre-Closing Services Amount Statement”. 

(h) Section 2.7(m) shall be amended by (A) deleting the words “September Pre-Closing Services Amount
Statement” and replacing them with the words “October Pre-Closing Services Amount Statement” and (B) deleting the words “September 30, 2011” and replacing them with the words “October 14, 2011”. 

(i) Section 6.21(b) shall be amended by deleting the words “September 30, 2011” and replacing them with
the words “October 14, 2011”. 
 2. No Implied Amendments. Except as specifically amended by
this Amendment, the Agreement shall remain in full force and effect in accordance with its terms and is hereby ratified and confirmed. All references to “the date hereof” in the Agreement shall continue to refer to the date of the
Agreement before any amendment, consent or waiver. 
 3. Effectiveness of Amendment. This Amendment shall
be deemed to be a modification to the Agreement in accordance with Section 10.14 of the Agreement. 
 4.
Benefit of the Amendment. This Amendment shall be binding upon and inure to the benefit of the Parties and their respective successors and permitted assigns. 

5. Headings. The headings used in this Amendment are for reference purposes only and shall not affect in any way
the meaning or interpretation of this Amendment. 
 6. Governing Law. This Amendment shall be governed
by, and construed in accordance with, the law of the State of Delaware applicable to contracts to be carried out wholly within such State. 

  
 2 

 7. Counterparts. This Amendment may be executed simultaneously in
multiple counterparts, and in separate counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. 

8. References to Agreement. On and after the date hereof, each reference in the Agreement to “this
Agreement,” “hereunder,” “hereof” or words of like import referring to the Agreement shall mean the Agreement as amended by this Amendment. 
 [signature pages follow] 

  
 3 

 IN WITNESS WHEREOF, the Parties have caused this Amendment No. 5 to Acquisition
Agreement to be executed as of the date first above written. 
  

			
	ELOYALTY, LLC
		
	By:	 	/s/    JOHN R. TROKA JR.        
	Name:	 	John R. Troka, Jr.
	 Title:
	 	Interim Chief Financial Officer

  

			
	TELETECH HOLDINGS, INC.
		
	By:	 	/s/    JOHN R. TROKA JR.        
	Name:	 	John R. Troka, Jr.
	 Title:
	 	Interim Chief Financial Officer

  

			
	MATTERSIGHT CORPORATION
		
	By:	 	/s/    WILLIAM B. NOON         
	Name:	 	William B. Noon
	Title:	 	Vice President and Chief Financial Officer

 [Signature Page to Amendment No. 5 to Acquisition Agreement]Loan and Security Agreement

 Exhibit 10.23 
 Portions of this exhibit marked [*] are requested to be treated confidentially. 

LOAN AND SECURITY AGREEMENT 
 THIS LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of August 18, 2011 (the “Closing Date”) by and among MIDCAP FUNDING III, LLC, a Delaware
limited liability company, with an office located at 7735 Old Georgetown Road, Suite 400, Bethesda, Maryland 20814 (“MidCap”), as administrative agent (“Agent”), the Lenders listed on Schedule 1 hereto and
otherwise party hereto from time to time (each a “Lender”, and collectively the “Lenders”), and FURIEX PHARMACEUTICALS, INC., a Delaware corporation, APBI HOLDINGS, LLC, a North Carolina limited
liability company, DEVELOPMENT PARTNERS, LLC, a Delaware limited liability company, and GENUPRO, INC., a North Carolina corporation (either individually or collectively as the context may require, the “Borrower”),
provides the terms on which Lenders agree to lend to Borrower and Borrower shall repay Lenders. The parties agree as follows: 
  

	 	1.	ACCOUNTING AND OTHER TERMS 

 Accounting terms not defined in this Agreement shall be construed in accordance with GAAP. Calculations and determinations must be made in accordance with GAAP. Capitalized terms not otherwise defined in
this Agreement shall have the meanings set forth in Section 14. All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein. 

 

	 	2.	LOAN AND TERMS OF PAYMENT 

 2.1 Promise to Pay. Borrower hereby unconditionally promises to pay to each Lender in accordance with its respective Pro Rata Share, the outstanding principal amount of all Credit Extensions
made by the Lenders, and accrued and unpaid interest thereon, and any other amounts due hereunder as and when due in accordance with this Agreement. 
 2.2 Term Loans. 
 (a) Availability. Subject to the
terms and conditions of this Agreement, during the Draw Period, the Lenders agree, severally and not jointly, to make one or more term loans to Borrower in an aggregate amount up to FIFTEEN MILLION AND NO/100 Dollars ($15,000,000.00) according to
each Lender’s Term Loan Commitment as set forth on Schedule 1 hereto (such term loans are hereinafter referred to singly as a “Term Loan”, and collectively as the “Term Loans”). After repayment, no Term
Loan may be re-borrowed. The Term Loans shall be made available to Borrower in two tranches. The first tranche (“Tranche One”) shall be in an amount equal to TEN MILLION AND NO/100 Dollars ($10,000,000.00) and shall be advanced on
the Closing Date. The second tranche (“Tranche Two”) shall be in an amount equal to FIVE MILLION AND NO/100 Dollars ($5,000,000.00) and shall be advanced to Borrower in a single sum during the Draw Period, immediately after the
Tranche Two Eligibility Date, so long as all of the conditions to funding set forth in Section 3.2 have been met or waived by Agent and Lenders. 

(b) Interest Payments and Repayment. Commencing on the first (1st) Payment Date following the Funding Date of Tranche One and of
Tranche Two, respectively, and continuing on the Payment Date of each successive month thereafter through and including the Maturity Date, Borrower shall make monthly payments of interest to each Lender in accordance with its respective Pro Rata
Share, in arrears, and calculated as set forth in Section 2.3. Commencing on the Amortization Date, and continuing on the Payment Date of each successive month thereafter through and including the Maturity Date, Borrower shall make consecutive
monthly payments of principal to each Lender in accordance with its respective Pro Rata Share, as calculated by Agent based upon: (i) the amount of such Lender’s Term Loans, (ii) the effective rate of interest, as determined in
Section 2.3, and (iii) a straight-line amortization schedule for each Credit Extension beginning on the Amortization Date and ending on the Maturity Date. All unpaid principal and accrued interest with respect to the Term Loans is due and
payable in full on the Maturity Date. The Term Loans may be prepaid only in accordance with Sections 2.2(c) and 2.2(d). 

 (c) Mandatory Prepayments. If the Term Loans are accelerated
following the occurrence of an Event of Default, Borrower shall immediately pay to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of the Term Loans and all other
Obligations, and all accrued and unpaid interest thereon, plus (ii) the Final Payment, plus (iii) the Prepayment Fee, plus (iv) all other sums that shall have become due and payable, including Lenders’
Expenses. 
 (d) Permitted Prepayment of Loans. Borrower shall have the option to prepay all, but not less
than all, of the Term Loans advanced by the Lenders under this Agreement; provided, however, that Borrower (i) provides written notice to Agent of its election to prepay the Term Loans at least ten (10) days prior to such
prepayment, and (ii) pays to each Lender in accordance with its respective Pro Rata Share, on the date of such prepayment, an amount equal to the sum of: (A) all outstanding principal of the Term Loans and all other Obligations, and all
accrued interest thereon, plus (B) the Final Payment, plus (C) the Prepayment Fee, plus (D) all other sums that shall have become due and payable, including Lenders’ Expenses. 

2.3 Payment of Interest on the Credit Extensions. 

(a) Computation of Interest. Interest on the Credit Extensions and all fees payable hereunder shall be computed on
the basis of a 360-day year and the actual number of days elapsed in the period during which such interest accrues. In computing interest on any Credit Extension, the date of the making of such Credit Extension shall be included and the date of
payment shall be excluded; provided, however, that if any Credit Extension is repaid on the same day on which it is made, such day shall be included in computing interest on such Credit Extension. 

(b) Interest Rate Determination. Subject to the provisions of Section 2.3(c) below, each Term Loan shall bear
interest at a fixed rate on the outstanding principal amount thereof from the Funding Date for such Term Loan until paid in full at a rate per annum equal to the sum of (i) the greater of (A) the LIBOR Rate in effect as of the applicable
Interest Rate Determination Date and (B) three percent (3.0%), plus (ii) the LIBOR Rate Margin. As of each Interest Rate Determination Date, Agent shall determine (which determination shall, absent manifest error in calculation, be
final, conclusive and binding upon all parties) the interest rate that shall apply to the Term Loan. In the event that Agent shall have determined (which determination shall be final and conclusive and binding upon all parties hereto), as of any
Interest Rate Determination Date with respect to any Term Loan, that adequate and fair means do not exist for ascertaining the interest rate applicable to such Term Loan on the basis provided for in the definition of Base LIBOR Rate, then Agent may
select a comparable replacement index and corresponding margin. 
 (c) Default Rate. Upon the occurrence
and during the continuance of an Event of Default, at the election of the Agent or Required Lenders, Obligations shall bear interest at a rate per annum that is four percent (4.0%) above the rate that is otherwise applicable thereto (the
“Default Rate”). Any such election to apply the Default Rate by Agent or Required Lenders may, in Agent’s or Required Lenders’ sole discretion, become effective retroactively as of the date of such Event of Default having
occurred. Payment or acceptance of the increased interest rate provided in this Section 2.3(c) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights
or remedies of Agent or Lenders. 
 (d) Debit of Accounts. Any Lender may debit any of Borrower’s
Deposit Accounts, including the Designated Deposit Account, for principal and interest payments when due or any other amounts Borrower owes the Lenders under the Loan Documents when due. These debits shall not constitute a set-off. 

(e) Payments. Payments of principal and/or interest received after 12:00 Noon Eastern Standard Time are considered
received at the opening of business on the next Business Day. When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid.
All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest made hereunder and pursuant to any other Loan Document, and all fees, expenses, indemnities and reimbursements, shall be
made without set-off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds. All payments required under this Agreement are to be made directly to Agent unless otherwise directed by Agent in writing.

  
 2 

 (f) Maximum Lawful Rate. In no event shall the interest charged
hereunder, with respect to the Term Loans and corresponding promissory notes (if any) or any other obligations of Borrower under any of the Loan Documents exceed the maximum amount permitted under the Laws of the State of Maryland. Notwithstanding
anything to the contrary herein or elsewhere, if at any time the rate of interest payable hereunder or under any promissory note or other Loan Document (the “Stated Rate”) would exceed the highest rate of interest permitted under
any applicable Law to be charged (the “Maximum Lawful Rate”), then for so long as the Maximum Lawful Rate would be so exceeded, the rate of interest payable shall be equal to the Maximum Lawful Rate; provided, however, that
if at any time thereafter the Stated Rate is less than the Maximum Lawful Rate, Borrower shall, to the extent permitted by Law, continue to pay interest at the Maximum Lawful Rate until such time as the total interest received is equal to the total
interest which would have been received had the Stated Rate been (but for the operation of this provision) the interest rate payable. Thereafter, the interest rate payable shall be the Stated Rate unless and until the Stated Rate again would exceed
the Maximum Lawful Rate, in which event this provision shall again apply. In no event shall the total interest received by any Lender exceed the amount which it could lawfully have received, had the interest been calculated for the full term hereof
at the Maximum Lawful Rate. If, notwithstanding the prior sentence, any Lender has received interest hereunder in excess of the Maximum Lawful Rate, then such excess amount shall be applied to the reduction of the principal balance of such
Lender’s Term Loan or to other amounts (other than interest) payable hereunder, and if no such principal or other amounts are then outstanding, such excess or part thereof remaining shall be paid to Borrower. In computing interest payable with
reference to the Maximum Lawful Rate applicable to any Lender, such interest shall be calculated at a daily rate equal to the Maximum Lawful Rate divided by the number of days in the year in which such calculation is made. 

2.4 Fees and Expenses. Borrower shall pay to each Lender: 

(a) Origination Fee. A non-refundable origination fee to each Lender, in accordance with its respective Pro Rata
Share, equal to the product of (i) one half of one percent (0.50%) multiplied by (ii) the aggregate Term Loan Commitment on the Closing Date that is funded by the Lenders, of which fifty thousand and no/100 dollars
($50,000.00) shall be due and payable on the Funding Date of Tranche One, and twenty-five thousand and no/100 dollars ($25,000.00) shall be due and payable if and on the date when the Funding Date of Tranche Two occurs; 

(b) Final Payment. The Final Payment, when due under Section 2.2(c) or 2.2(d), or otherwise on the Tranche Two
Maturity Date, to each Lender, in accordance with its respective Pro Rata Share; 
 (c) Prepayment Fee.
The Prepayment Fee, if and when due under Section 2.2(c) or 2.2(d), to each Lender, in accordance with its respective Pro Rata Share immediately prior to application of the corresponding prepayment; and 

(d) Lenders’ Expenses. All of Lenders’ Expenses incurred through and after the Closing Date, when due
(and in the absence of any other due date specified herein, such Lenders’ Expenses shall be due upon demand). 
 2.5
Additional Costs. If any new Law or regulation increases a Lender’s costs or reduces its income for any Term Loan, Borrower shall pay the increase in cost or reduction in income or additional expense; provided, however, that
Borrower shall not be liable for any amount attributable to any period before one hundred eighty (180) days prior to the date such Lender notifies Borrower of such increased costs. Each Lender agrees that it shall allocate any increased costs
among its customers similarly affected in good faith and in a manner consistent with such Lender’s customary practice. 

2.6 Payments and Taxes. Any and all payments made by Borrower under this Agreement or any other Loan Document shall be made free
and clear of and without deduction for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by any governmental authority (including any interest, additions to tax or
penalties applicable thereto) other than any taxes imposed on or measured by any Lender’s overall net income and franchise taxes imposed on it (in lieu of net income taxes), by a jurisdiction (or any political subdivision thereof) as a result
of any Lender being organized or resident, conducting business (other than a business deemed to arise from such Lender having executed, delivered 

  
 3 

 
or performed its obligations or received a payment under, or enforced, or otherwise with respect to, this Agreement or any other Loan Document) or having its principal office in such jurisdiction
(“Indemnified Taxes”). If any Indemnified Taxes shall be required by Law to be withheld or deducted from or in respect of any sum payable under this Agreement or any other Loan Document to any Lender, (a) an additional amount
shall be payable as may be necessary so that, after making all required withholdings or deductions (including withholdings or deductions applicable to additional sums payable under this Section) such Lender receives an amount equal to the sum it
would have received had no such withholdings or deductions been made, (b) Borrower shall make such withholdings or deductions, (c) Borrower shall pay the full amount withheld or deducted to the relevant taxing authority or other authority
in accordance with applicable Law, and (d) Borrower shall deliver to such Lender evidence of such payment. Borrower’s obligation hereunder shall survive the termination of this Agreement. 

2.7 Secured Promissory Notes. Each Term Loan shall be evidenced by a Secured Promissory Note in the form attached as
Exhibit D hereto (each a “Secured Promissory Note”), and shall be repayable as set forth herein. Borrower irrevocably authorizes each Lender to make or cause to be made, on or about the Funding Date of any Term Loan or at the
time of receipt of any payment of principal on such Lender’s Secured Promissory Note, an appropriate notation on such Lender’s Secured Promissory Note Record reflecting the making of such Term Loan or (as the case may be) the receipt of
such payment. The outstanding amount of each Term Loan set forth on such Lender’s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender, but the failure to record, or any
error in so recording, any such amount on such Lender’s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower hereunder or under any Secured Promissory Note to make payments of principal of or interest
on any Secured Promissory Note when due. Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note, Borrower shall issue, in lieu thereof, a replacement Secured Promissory
Note in the same principal amount thereof and of like tenor. 
  

	 	3.	CONDITIONS OF LOANS 

3.1 Conditions Precedent to Initial Credit Extension. Each Lender’s obligation to make a Term Loan is subject to the condition
precedent that Agent shall consent to or shall have received, in form and substance satisfactory to Agent and Lenders, such documents, and completion of such other matters, as Agent may reasonably deem necessary or appropriate, including, without
limitation: 
 (a) duly executed original signatures to this Agreement, the Perfection Certificate and the other
Loan Documents to which Borrower is a party; 
 (b) duly executed original Secured Promissory Notes in favor of
each Lender with a face amount equal to such Lender’s Term Loan Commitment; 
 (c) duly executed original
signatures to the Control Agreements with Silicon Valley Bank and Merrill Lynch; 
 (d) a pledge agreement, in
form and substance reasonably satisfactory to Agent, executed by each Loan Party and pledging to Agent, for the benefit of itself and the Lenders, a security interest in (a) 100% of the shares of the outstanding capital stock or limited
liability company interests of any class of each Subsidiary of each Loan Party that is incorporated under the laws of any State of the United States or the District of Columbia (other than the [*]), (b) shares of the outstanding capital stock
or limited liability company interests of any class of each Foreign Subsidiary that constitute 65% of the total combined voting power of all capital stock or limited liability company interests of all classes of such Foreign Subsidiary
(provided, that with respect to any Foreign Subsidiary, to the extent that there is no material increase in Borrower’s federal income tax liability from a pledge or one hundred percent (100%) of such shares or equity interests of
such Foreign Subsidiary, such pledge shall be for one-hundred percent (100%) of such Foreign Subsidiary’s outstanding voting and non-voting capital stock or limited liability company interests) and (c) any and all Indebtedness (as
defined below) owing to Loan Parties (the “Pledge Agreement”) 

  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 4 

 (e) the formation documents of Borrower certified by the Secretary of State
of the state of organization of Borrower as of a date no earlier than thirty (30) days prior to the Closing Date; 
 (f) good standing certificates dated as of a date no earlier than thirty (30) days prior to the Closing Date from each Borrower’s state of organization and each state in which the nature of
Borrower’s business requires it to be qualified to transact business; 
 (g) duly executed original
signatures to the completed Borrowing Resolutions for Borrower; 
 (h) certified copies, dated as of a recent
date, of financing statement searches, as Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in
connection with the initial Credit Extension, will be terminated or released; 
 (i) a landlord’s consent
executed by PPD in favor of Agent in respect of Borrower’s facilities at 3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560; 
 (j) a legal opinion of Borrower’s counsel dated as of the Closing Date together with the duly executed original signatures thereto; 

(k) evidence satisfactory to Agent that the insurance policies required by Section 6.5 hereof are in full force and
effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Agent, for the ratable benefit of Lenders; and 

(l) payment of the origination fee described in Section 2.4(a) and the Lenders’ Expenses described in
Section 2.4(d). 
 3.2 Conditions Precedent to all Credit Extensions. The obligation of each Lender to make each
Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent: 

(a) timely receipt by the Agent of an executed Payment/Advance Form in the form of Exhibit B attached hereto;

 (b) the representations and warranties in Section 5 shall be true, correct and complete in all material
respects on the date of the Payment/Advance Form and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or
modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Default
or Event of Default shall have occurred and be continuing or result from the Credit Extension. Each Credit Extension shall constitute Borrower’s representation, warranty and confirmation that the conditions set forth in this clause
(b) have been satisfied; and 
 (c) in such Lender’s sole discretion, there has not been any Material
Adverse Change or any material impairment in the general affairs, management, results of operation, financial condition or the prospect of repayment of the Obligations, or any material adverse deviation by Borrower from the most recent business plan
of Borrower presented to and accepted by Agent. 
 3.3 Covenant to Deliver. Borrower agrees to deliver to Agent each item
required to be delivered to Agent under this Agreement as a condition precedent to any Credit Extension. Borrower expressly agrees that a Credit Extension made prior to the receipt by Agent of any such item shall not constitute a waiver by the
Lenders of Borrower’s obligation to deliver such item, and any such Credit Extension in the absence of a required item shall be made in Agent’s sole discretion. 

  
 5 

 3.4 Procedures for Borrowing. Subject to the prior satisfaction of all other
applicable conditions to the making of a Term Loan set forth in this Agreement, to obtain a Term Loan, Borrower shall notify Agent (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12:00 noon Eastern time ten
(10) Business Days prior to the date the Term Loan is to be made. Together with any such electronic or facsimile notification, Borrower shall deliver to Agent by electronic mail or facsimile a completed Payment/Advance Form executed by a
Responsible Officer or his or her designee. Upon receipt of a Payment/Advance Form, Agent shall promptly provide a copy of the same to each Lender. Agent may rely on any telephone notice given by a person whom Agent reasonably believes is a
Responsible Officer or designee. 
  

	 	4.	CREATION OF SECURITY INTEREST 

 4.1 Grant of Security Interest. Borrower hereby grants to Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing
security interest in, and pledges to Agent, for the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. Borrower represents, warrants, and
covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that may have priority by operation of applicable Law. If
Borrower shall acquire a commercial tort claim (as defined in the Code), Borrower shall promptly notify Agent in a writing signed by Borrower of the general details thereof (and further details as may be reasonably required by Agent) and grant to
Agent, for the ratable benefit of the Lenders, in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Agent. 

4.2 Authorization to File Financing Statements. Borrower hereby authorizes Agent to file financing statements, without notice to
Borrower, with all appropriate jurisdictions to perfect or protect Agent’s and each Lender’s interest or rights hereunder, including a notice that any disposition of the Collateral not permitted hereunder, by either Borrower or any other
Person, shall be deemed to violate the rights of Agent and the Lenders under the Code. 
  

	 	5.	REPRESENTATIONS AND WARRANTIES 

 Borrower represents and warrants as follows at all times unless expressly provided below: 
 5.1 Due Organization, Authorization: Power and Authority. 

(a) Borrower and each of its Subsidiaries are duly existing and in good standing, as Registered Organizations in their
respective jurisdictions of formation and are qualified and licensed to do business and are in good standing in any jurisdiction in which the conduct of their business or their ownership of property requires that they be qualified except where the
failure to be so qualified could not reasonably be expected to result in a Material Adverse Change. Borrower represents and warrants that (i) Borrower’s exact legal name is that indicated on Schedule 5.1 and on the signature page
hereof; (ii) Borrower is an organization of the type and is organized in the jurisdiction set forth on Schedule 5.1; (iii) Schedule 5.1 accurately sets forth Borrower’s organizational identification number or accurately
states that Borrower has none; (iv) Schedule 5.1 accurately sets forth Borrower’s place of business, or, if more than one, its chief executive office as well as Borrower’s mailing address (if different than its chief executive
office); and (v) Borrower has not, in the past five (5) years, changed its jurisdiction of formation, organizational structure or type, or any organizational number assigned by its jurisdiction. Further, in connection with this Agreement,
Borrower has delivered to Agent a completed Perfection Certificate signed by Borrower (the “Perfection Certificate”). All other information set forth on the Perfection Certificate pertaining to Borrower and each of its Subsidiaries
is accurate and complete (it being understood and agreed that Borrower may from time to time update certain information in the Perfection Certificate after the Closing Date, to the extent permitted by one or more specific provisions in this
Agreement). 
 (b) The execution, delivery and performance by Borrower of the Loan Documents to which it is a
party have been duly authorized, and do not (i) conflict with any of Borrower’s Operating Documents; (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law; (iii) contravene,
conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any 

  
 6 

 
Governmental Authority by which Borrower or any of its Subsidiaries or any of their property or assets may be bound or affected; (iv) require any action by, filing, registration, or
qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect); or (v) constitute an event of default under any material
agreement by which Borrower or any of its Subsidiaries or their respective properties is bound. Borrower is not in default under any agreement to which it is a party or by which it is bound in which the default could reasonably be expected to have a
Material Adverse Change. 
 5.2 Collateral. 

(a) Collateral Accounts. Borrower has good title to, has rights in, and has the power to grant a security interest
in and transfer each item of the Collateral upon which it purports to grant a Lien hereunder, free and clear of any and all Liens, except Permitted Liens. Borrower has no Deposit Accounts, Securities Accounts, Commodity Accounts or other investment
accounts other than the Collateral Accounts with the banks and/or financial institutions listed on Schedule 5.2(a), for which Borrower has given Agent notice and taken such actions as are necessary to grant to Agent, for the ratable benefit
of Lenders, a perfected security interest therein; provided, that subject to the post closing requirement set forth as paragraph (a) on Schedule 6.12, Borrower shall not be required to enter into a Control Agreement with respect to the
Collateral Accounts located at Branch Banking & Trust Company that are listed on Schedule 5.2 (a). 

(b) Accounts. The Accounts are bona fide, existing obligations of the Account Debtors. 

(c) Inventory. All Sale Inventory is in all material respects of good and marketable quality, free from material
defects. All Development Inventory manufactured for use in and/or used in clinical trials has been synthesized in accordance with current ‘Good Manufacturing Practices’ making it suitable for use in humans. 

(d) Intellectual Property and License Agreements. A list of all of Borrower’s copyrights, copyright
applications, trademarks, trademark applications, patents and patent applications (“Subject Intellectual Property”) and all license agreements (including all in-bound license agreements, but excluding over-the-counter software that is
commercially available to the public) is set forth on Schedule 5.2(d), which indicates, for each item of property: (i) the name of Borrower owning such Subject Intellectual Property or licensee to such license agreement;
(ii) Borrower’s identifier for such property (i.e., name of patent, license, etc.), (iii) whether such property is Subject Intellectual Property (or application therefor) owned by Borrower or is property to which Borrower has rights
pursuant to a license agreement, and (iv) the expiration date of such Subject Intellectual Property or license agreement. In the case of any license agreement, Schedule 5.2(d) further indicates, for each: (A) the name and address of
the licensor, (B) the name and date of the license agreement pursuant to which Intellectual Property is licensed, (C) whether or not such license agreement grants an exclusive license to Borrower, and (D) whether there are any
restrictions in such license agreement as to the ability of Borrower to grant a security interest in and/or to transfer any of its rights as a licensee under such license agreement. Except as noted on Schedule 5.2(d), Borrower is the sole
owner of its Subject Intellectual Property, except for non-exclusive licenses granted to its customers in the Ordinary Course of Business. Each Patent is properly filed and maintained, no part of the Subject Intellectual Property has been judged
invalid or unenforceable, in whole or in part, and to the best of Borrower’s knowledge (x) no claim has been made that any part of the Subject Intellectual Property violates the rights of any third party, except to the extent such claim
could not reasonably be expected to result in a Material Adverse Change and (y) each Patent is valid and enforceable. 
 (e) Location of Collateral. On the Closing Date, the Collateral, exclusive of Development Inventory, is located at the address(es) identified on Schedule 5.2(e), and is not in the possession
of any third party bailee (such as a warehouse) except as disclosed Schedule 5.2(e), and as of the Closing Date, no such third party bailee possesses components of the Collateral, exclusive of Development Inventory, in excess of Twenty-Five
Thousand Dollars ($25,000) or which constitutes Borrowers’ Books. None of the components of the Collateral, other than Development Inventory, shall be maintained at locations other than as disclosed Schedule 5.2(e) on the Closing Date or
as permitted pursuant to Section 7.2. In the event that Borrower, after the Closing Date, intends to store or otherwise deliver any portion of the Collateral, other than Development Inventory, to a bailee in excess of One Hundred Thousand
Dollars ($100,000) or which constitutes Borrowers’ Books, then Borrower will first receive the written consent of Agent and such bailee must execute and deliver a bailee agreement in form and substance

  
 7 

 
satisfactory to Agent in its sole discretion. Without limiting the foregoing, in the event that (x) PPD is in default under its lease for the premises located at 3900 Paramount Parkway,
Suite 150, Morrisville, North Carolina 27560 or (y) such lease is terminated and Borrower enters into a new or separate lease with the owner of such premises or if the owner confirms Borrower’s sublease shall remain in effect, then in
either case of (x) or (y), upon the request of Agent, Borrower shall obtain a landlord waiver in form and substance satisfactory to Agent executed by such owner and by Borrower in favor of Agent. 

5.3 Litigation. Except for routine proceedings (which shall not include any enforcement action or other adverse proceedings) with
the FDA or other similar regulatory agencies, or as otherwise disclosed on Schedule 5.3 hereto, there are no actions or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or any
of its Subsidiaries involving more than One Hundred Thousand Dollars ($100,000.00). 
 5.4 No Material Deterioration in
Financial Condition; Financial Statements. All consolidated financial statements for Borrower and any of its Subsidiaries delivered to Agent fairly present, in conformity with GAAP, in all material respects Borrower’s consolidated financial
condition and Borrower’s consolidated results of operations; provided, however, the interim financial statements of Borrower lack footnotes and are subject to year-end audit adjustments, all in accordance with GAAP . There has not been
any material deterioration in Borrower’s consolidated financial condition since the date of the most recent financial statements and projections submitted to Agent. 
 5.5 Solvency. The fair salable value of Borrower’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities. After giving effect to the transactions
described in this Agreement, (a) Borrower is not left with unreasonably small capital in relation to its business as presently conducted, and (b) Borrower is able to pay its debts (including trade debts) as they mature. 

5.6 Regulatory Compliance. 
 (a) Borrower is not an “investment company” or a company “controlled” by an “investment company” under the Investment Company Act of 1940, as amended. Borrower is not engaged
as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors). Borrower has complied in all material respects with the Federal Fair Labor Standards Act. Neither
Borrower nor any of its Subsidiaries is a “holding company” or an “affiliate” of a “holding company” or a “subsidiary company” of a “holding company”, as each term is defined and used in the Public
Utility Holding Company Act of 2005. Borrower has not violated any Laws, ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change. None of Borrower’s or any of its Subsidiaries’ properties
or assets has been used by Borrower or any Subsidiary or, to Borrower’s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable Laws.
Borrower has obtained all Required Permits, or has contracted with third parties holding Required Permits, necessary for compliance with all Laws and all such Required Permits are current. Borrower and each of its Subsidiaries have obtained all
consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted. 

(b) None of the Borrower, its Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the
transactions contemplated by this Agreement is (i) in violation of any Anti-Terrorism Law, (ii) engages in or conspires to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate,
any of the prohibitions set forth in any Anti-Terrorism Law, or (iii) is a Blocked Person. Neither Borrower nor, to the knowledge of Borrower, any of its Affiliates or agents acting or benefiting in any capacity in connection with the
transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any
transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law. 
 5.7 Subsidiaries; Investments. Borrower does not own any stock, partnership interest or other equity securities, except for Permitted Investments. 

  
 8 

 5.8 Tax Returns and Payments; Pension Contributions. Borrower has timely filed all
required tax returns and reports, and Borrower and its Subsidiaries have timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower, except that Borrower may defer payment of any contested taxes
so long as Borrower (a) in good faith contests its obligation to pay such taxes by appropriate proceedings promptly and diligently instituted and conducted, (b) notifies Agent in writing of the commencement of, and any material development
in, the proceedings, and (c) posts bonds or takes any other steps required to prevent the governmental authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a “Permitted Lien”.
Borrower is unaware of any claims or adjustments proposed for any of Borrower’s prior tax years which could result in additional taxes becoming due and payable by Borrower. Borrower has paid all amounts required to fund all of its present
pension, profit sharing and deferred compensation plans in accordance with their terms, and Borrower has not withdrawn from participation in, and has not permitted partial or complete termination of, or permitted the occurrence of any other event
with respect to, any such plan which could reasonably be expected to result in any liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. 

5.9 Use of Proceeds. Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general
business requirements, and not for personal, family, household or agricultural purposes. 
 5.10 Full Disclosure. No
written representation, warranty or other statement of Borrower in any certificate or written statement given to Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written
certificates and written statements given to Agent or any Lender, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it
being recognized that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may
differ from the projected or forecasted results). 
 5.11 Regulatory Developments. 

(a) All Products and all Required Permits are listed on Schedule 5.11 (as updated from time to time pursuant to
Section 6.2(e)), and Borrower has delivered to Agent a copy of all Required Permits as of the date hereof and to the extent requested by Agent pursuant to Section 6.2(e). 

(b) Without limiting the generality of Section 5.6 above, with respect to any Development Compound or Sale Compound of Borrower,
Borrower has received and such Product is the subject of, all Required Permits needed in connection with the testing and/or manufacture, as applicable, with respect to such Product as such testing is currently being conducted by or on behalf of
Borrower with respect to Development Compounds or Sale Compounds, and Borrower has not received any notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is conducting an investigation or
review of (i) Borrower’s manufacturing facilities and processes for any Sale Compound which have disclosed any material deficiencies or violations of Laws and/or the Required Permits related to the manufacture of such Sale Compound, or
(ii) any such Required Permit or that any such Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation stating that the testing of such Development Compound or manufacturing of
such Sale Compound by Borrower should cease. 
 (c) Without limiting the generality of Section 5.6 above, with respect to
any Sale Compound that may be marketed or sold by Borrower, Borrower has received, and such Sale Compound is the subject of, all Required Permits needed in connection with the marketing and sales of such Sale Compound that may be marketed or sold by
Borrower, and Borrower has not received any notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is conducting an investigation or review of any such Required Permit or approval or that
any such Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation stating that such marketing or sales of such Sale Compound cease or that such Sale Compound be withdrawn from the
marketplace. 

  
 9 

 (d) Without limiting the generality of Section 5.6 above, there have been no serious
adverse clinical test results related to the safety or efficacy of Development Compounds resulting in the termination of all clinical studies for such Development Compound or recalls of Sale Compounds (whether voluntary or involuntary), in each case
which have resulted in or could reasonably be expected to result in a Material Adverse Change. 
 (e) Borrower has not
experienced any material failures in its manufacturing of any Sale Compound such that the amount of such Sale Compound successfully manufactured by Borrower in accordance with all specifications thereof and the required payments related thereto in
any month shall decrease significantly with respect to the quantities of such Sale Compound produced in the prior month, which such decrease has resulted in or could reasonably be expected to result in a Material Adverse Change. 

 

	 	6.	AFFIRMATIVE COVENANTS 

 Borrower covenants and agrees to do all of the following: 
 6.1 Organization
and Existence; Government Compliance. 
 (a) Maintain its and all its Subsidiaries’ legal existence and
good standing in their respective jurisdictions of formation and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to result in a Material Adverse Change. Borrower shall comply, and have each
Subsidiary comply, with all Laws, ordinances and regulations to which it is subject, the noncompliance with which could reasonably be expected to result in a Material Adverse Change. 

(b) Obtain and keep in full force and effect, all of the Governmental Approvals, if any, necessary for the performance by
Borrower of its obligations under the Loan Documents to which it is a party and the grant of a security interest to Agent for the ratable benefit of the Lenders, in all of the Collateral. Borrower shall promptly provide copies of any such obtained
Governmental Approvals to Agent. 
 (c) In connection with the testing of each Development Compound or the
manufacture, marketing or sale of each and any Sale Compound by Borrower, Borrower shall comply fully and completely in all respects with all Required Permits at all times issued by any Governmental Authority the noncompliance with which could
reasonably be expected to result in a Material Adverse Change, specifically including the FDA, with respect to such testing of any Development Compound or such manufacture, marketing or sales of any Sale Compound by Borrower as such activities are
at any such time being conducted by Borrower. 
 6.2 Financial Statements, Reports, Certificates. 

(a) Deliver to Agent: (i) as soon as available, but no later than forty-five (45) days after the last day of
each month, a company prepared consolidated balance sheet, income statement and cash flow statement covering Borrower’s consolidated operations for such month certified by a Responsible Officer and in a form reasonably acceptable to Agent;
(ii) as soon as available, but no later than one hundred fifty (150) days after the last day of Borrower’s fiscal year, audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified
opinion on the financial statements from an independent certified public accounting firm acceptable to Agent in its reasonable discretion; (iii) as soon as available after approval thereof by Borrower’s Board of Directors, but no later
than ninety (90) days after the last day of Borrower’s fiscal year, Borrower’s financial projections for the current fiscal year as approved by Borrower’s Board of Directors; (iv) other than with respect to reports made
available in accordance with clause (v), below, within five (5) days of delivery, copies of all statements, reports and notices made available to all of Borrower’s security holders; (v) so long as Borrower is subject to the reporting
requirements under the Securities Exchange Act of 1934, as amended, within five (5) days of filing, all reports on Form 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission or a link thereto on Borrower’s or another website
on the Internet; (vi) a prompt report of any legal actions pending or threatened against Borrower or any of its Subsidiaries that could be reasonably expected to result in damages or costs to Borrower or any of its Subsidiaries of One Hundred
Thousand Dollars ($100,000) or more or could result in a Material Adverse Change; and (vii) budgets, sales projections, operating plans and other financial information reasonably requested by Agent. 

  
 10 

 (b) Within forty-five (45) days after the last day of each month,
deliver to Agent with the monthly financial statements described above, a duly completed Compliance Certificate signed by a Responsible Officer. 
 (c) Keep proper books of record and account in accordance with GAAP in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities.
Borrower shall allow, at the sole cost of Borrower, Agent and Lenders to visit and inspect (such visit or inspection to be during normal business hours so long as no Default or Event of Default exists) any of its properties, to examine and make
abstracts or copies from any of Borrower’s books and records, to conduct a collateral audit and analysis of its operations and the Collateral to verify the amount and age of the Accounts, the identity and credit of the respective Account
Debtors, to review the billing practices of Borrower and to discuss its respective affairs, finances and accounts with their respective officers, employees and independent public accountants as often as may reasonably be desired. Notwithstanding the
foregoing, such audits shall be conducted at Borrower’s expense no more often than once every twelve (12) months unless a Default or Event of Default has occurred and is continuing. 

(d) Within thirty (30) days of (i) acquiring and/or obtaining any new Subject Intellectual Property, or
(ii) enters into or becomes bound by any additional license agreement (other than products that are commercially available to the public), or upon any material change in Borrower’s existing Subject Intellectual Property, deliver to
Agent an updated Schedule 5.2(d) reflecting same. Borrower shall use its commercially reasonable efforts to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for (x) all licenses or agreements to be
deemed “Collateral” and for Agent to have a security interest in it that might otherwise be restricted or prohibited by Law or by the terms of any such license or agreement, whether now existing or entered into in the future, and
(y) Agent to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Agent’s rights and remedies under this Agreement and the other Loan Documents. 

(e) If, after the Closing Date, Borrower determines to manufacture, sell or market any new Sale Compound, Borrower shall
give prior written notice to Agent of such determination (which shall include a brief description of such Sale Compound, plus a list of all Required Permits relating to such new Sale Compound (and a copy of such Required Permits if requested by
Agent), along with a copy of an updated Schedule 5.11; provided, however, that if Borrower shall at any time obtain any new or additional Required Permits from the FDA, DEA, or parallel state or local authorities, or foreign
counterparts of the FDA, DEA, or parallel state or local authorities, with respect to any Product which has previously been disclosed to Agent, Borrower shall promptly give written notice to Agent of such new or additional Required Permits (along
with a copy thereof if requested by Agent). 
 6.3 Inventory; Returns. Keep all Sale Inventory in good and marketable
condition, free from material defects and keep all Development Inventory manufactured for use in and/or used in clinical trials synthesized in accordance with current ‘Good Manufacturing Practices’ and suitable for use in humans. Returns
and allowances between Borrower and its Account Debtors shall follow such customary practices as may be established by Borrower and consistent with industry practice if it engages in the sale of Sale Inventory. Borrower must promptly notify Agent of
all returns, recoveries, disputes and claims with respect to Sale Inventory that involve more than One Hundred Thousand Dollars ($100,000). 
 6.4 Taxes; Pensions. Timely file and require each of its Subsidiaries to timely file, all required tax returns and reports and timely pay, and require each of its Subsidiaries to timely file, all
foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower and each of its Subsidiaries, except for deferred payment of any taxes contested pursuant to the terms of Section 5.8 hereof, and shall deliver
to Agent, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms. 

6.5 Insurance. Keep its business and the Collateral insured for risks and in amounts standard for companies in Borrower’s
industry and location and as Agent may reasonably request. Insurance policies shall be in a form, with companies, and in amounts that are reasonably satisfactory to Agent. All property policies shall have a lender’s loss payable endorsement
showing Agent as lender loss payee and waive subrogation against Agent, and all liability policies shall show, or have endorsements showing, Agent, as an additional insured. All policies (or the loss payable and additional insured endorsements)
shall provide that the insurer shall endeavor to give Agent at least thirty (30) days notice before canceling, amending, or declining to renew its policy. At Agent’s request, Borrower shall deliver certified copies of policies and evidence
of all premium payments. Proceeds payable under any policy 

  
 11 

 
shall, at Agent’s option, be payable to Agent on behalf of the Lenders on account of the Obligations. If Borrower fails to obtain insurance as required under this Section 6.5 or to pay
any amount or furnish any required proof of payment to third persons and Agent, Agent may make all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Agent deems
prudent. 
 6.6 Operating Accounts. 

(a) Except for those Collateral Accounts listed on Schedule 5.2(a), maintain all of its, and all of its
Subsidiaries’, operating and other Deposit Accounts, Securities Accounts, Investment Accounts and Commodity Accounts with Silicon Valley Bank or its affiliates, as applicable. 

(b) Provide Agent five (5) days prior written notice before establishing any Collateral Account at or with any bank
or financial institution. In addition, for each Collateral Account that Borrower at any time maintains, Borrower shall cause the applicable bank or financial institution at or with which any Collateral Account is maintained to execute and deliver a
Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Agent’s Lien in such Collateral Account in accordance with the terms hereunder, which Control Agreement may not be terminated without prior
written consent of Agent. The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower’s employees and
identified to Agent by Borrower as such. 
 6.7 Protection of Intellectual Property Rights. Borrower shall own, or be
licensed to use or otherwise have the right to use, all Material Intellectual Property. All Subject Intellectual Property of Borrower is and shall be protected and/or duly and properly registered, filed or issued in the appropriate office and
jurisdictions for such registrations, filings or issuances, all in a manner consistent with industry standards for similar businesses except where the failure to do so would not reasonably be expected to result in a Material Adverse Change. Borrower
shall not become a party to, nor become bound by, any material license or similar agreement with respect to which Borrower is the licensee thereunder that prohibits or otherwise restricts Borrower from granting a security interest in Borrower’s
rights under such license agreement. Borrower shall at all times conduct its business without knowingly committing infringement of any Intellectual Property rights of others. Borrower shall, to the extent it determines, in the exercise of its
reasonable business judgment, that it is prudent to do the following: (a) protect, defend and maintain the validity and enforceability of its Intellectual Property; (b) promptly advise Agent in writing of material infringements of its
Intellectual Property; and (c) not allow any Material Intellectual Property to be abandoned, forfeited or dedicated to the public without Agent’s prior written consent. If Borrower (i) obtains any patent, registered trademark or
servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (ii) applies for any patent or the registration of any trademark or servicemark, then
Borrower shall concurrently provide written notice thereof to Agent in accordance with Section 6.2(d) and concurrently with such notice, shall provide to Agent copies of all applications that it filed for patents or for the registration of
trademarks, servicemarks, copyrights or mask works. 
 6.8 Litigation Cooperation. From the date hereof and continuing
through the termination of this Agreement, make available to Agent, without expense to Agent, Borrower and its officers, employees and agents and Borrower’s Books, to the extent that Agent may deem them reasonably necessary to prosecute or
defend any third-party suit or proceeding instituted by or against Agent with respect to any Collateral or relating to Borrower. 
 6.9 Notices of Litigation and Default. Borrower will give prompt written notice to Agent of any litigation or governmental proceedings pending or threatened (in writing) against Borrower which
would reasonably be expected to result in a Material Adverse Change. Without limiting or contradicting any other more specific provision of this Agreement, promptly (and in any event within three (3) Business Days) upon Borrower becoming aware
of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, Borrower shall give written notice to Agent of such occurrence, which such notice shall include a
reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default. 
 6.10 Creation/Acquisition of Subsidiaries. In the event Borrower or any Subsidiary creates or acquires any Subsidiary, Borrower and such Subsidiary shall promptly notify Agent of the creation
or acquisition of 

  
 12 

 
such new Subsidiary and, other than the [*], take all such action as may be reasonably required by Agent to cause each such domestic Subsidiary to become a co-Borrower hereunder or to guarantee
the Obligations of Borrower under the Loan Documents and, in each case, grant a continuing pledge and security interest in and to the assets of such Subsidiary (substantially as described on Exhibit A hereto); and Borrower shall grant
and pledge to Agent, for the ratable benefit of the Lenders, a perfected security interest in the stock, units or other evidence of ownership of each Subsidiary (other than the [*]). 

6.11 Further Assurances. 
 (a) Execute any further instruments and take further action as Agent reasonably requests to perfect or continue Agent’s Lien in the Collateral or to effect the purposes of this Agreement. 

(b) Deliver to Agent, within five (5) days after the same are sent or received, copies of all material
correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material adverse effect on any of the Governmental Approvals material to Borrower’s business or otherwise result in
a Material Adverse Change. 
 6.12 Post-Closing Obligations. Borrowers shall complete each of the post closing
obligations and/or deliver to Agent each of the documents, instruments, agreements and information listed on Schedule 6.12 attached hereto, on or before the date set forth for each such item thereon, each of which shall be completed or
provided in form and substance satisfactory to Agent and Lenders. 
  

	 	7.	NEGATIVE COVENANTS 

Borrower shall not do any of the following without the prior written consent of Agent and Required Lenders: 

7.1 Dispositions. Convey, sell, lease, transfer, assign, grant a security in or otherwise dispose of (collectively,
“Transfer”), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for (a) the sale, lease or disposition of Inventory in the Ordinary Course of Business; (b) the sale, lease or
disposition of worn-out or obsolete Equipment; (c) the payment of cash or Cash Equivalents in the Ordinary Course of Business solely for the payment of costs and expenses associated with operation of Borrower’s business, including without
limitation expenditures relating to (i) Borrower’s Phase I, Phase II and Phase III development activities and (ii) the acquisition (including in-licensing) of additional compounds so long as immediately after any such acquisition
Borrower [*] based on the financial projections delivered to Agent; (d) transfers of Intellectual Property pursuant to outbound license agreements with third parties in the Ordinary Course of Business so long as (i) Borrower receives not
less than $[*] of net cash payments from each such license agreement that grants rights with respect to the US market or globally which such amounts have been fully-earned and are non-refundable at the time such license agreement is consummated and
(ii) at all times Borrower shall have rights necessary to receive future milestone and royalty payments for at least two of Borrower’s existing Products (“Permitted IP Dispositions”); (e) in connection with Permitted
Liens; or (f) of the [*] and/or, solely if required pursuant to such transaction as a result of the termination of the [*] or the [*] thereunder, pursuant to and subject to the conditions of the [*]. Without limiting the foregoing, Borrower
agrees that it shall not grant a security interest or otherwise encumber any of its Intellectual Property without Agent’s and Required Lenders’ prior written consent, except as contemplated by and subject to the conditions of the [*].

 7.2 Changes in Business, Management, Ownership or Business Locations. (a) Other than the manufacture, marketing
and sale of Sale Inventory, engage in or permit any of its Subsidiaries to engage in any business other than the businesses currently engaged in by Borrower and such Subsidiary, as applicable, or reasonably related thereto; (b) liquidate or
dissolve; (c) (i) (A) have a change in any Responsible Officer position that does not result in a qualified replacement or (B) the failure to fill a vacancy with respect to any Responsible Officer position with a suitable qualified
replacement within (60) days following such vacancy, or (ii) enter into any transaction or series of related transactions which would constitute or cause a Change of Control; or (d) add any new

  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 13 

 
offices or business locations, including warehouses (where such new offices or business locations contain more than One Hundred Thousand Dollars ($100,000) in Borrower’s assets or property
or any of Borrowers’ Books unless, prior to the addition of such new office, business location or warehouse, Borrower obtains a landlord waiver in form and substance satisfactory to Agent executed by the owner of such premises and Borrower in
favor of agent (e) change its jurisdiction of organization; (f) other than the creation or acquisition of Subsidiaries in accordance with and subject to the conditions set forth in Section 6.10 of this Agreement, change its
organizational structure or type; (g) change its legal name; or (h) change any organizational number (if any) assigned by its jurisdiction of organization. 
 7.3 Mergers or Acquisitions. Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or
substantially all of the capital stock or property of another Person; provided, however, that a Subsidiary of Borrower may merge or consolidate into another Subsidiary that is a Loan Party or into Borrower, so long as (a) Borrower has
provided Agent with prior written notice of such transaction, (b) Borrower shall be the surviving legal entity, (c) Borrower’s tangible net worth is not thereby reduced, and (d) as long as no Event of Default is occurring prior
thereto or arises as a result therefrom. 
 7.4 Indebtedness. Create, incur, assume, or be liable for any Indebtedness,
or permit any Subsidiary to do so, other than Permitted Indebtedness. 
 7.5 Encumbrance. (a) Create, incur, allow,
or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, (b) permit any Collateral not to be subject
to the first priority security interest granted herein, or (c) enter into any agreement, document, instrument or other arrangement (except with or in favor of Agent) with any Person which directly or indirectly prohibits or has the effect of
prohibiting Borrower or any Subsidiary from collaterally assigning, mortgaging, pledging, granting a security interest in or Lien upon any of Borrower’s or any Subsidiary’s property (including, without limitation, Intellectual Property),
all of the foregoing except as is otherwise permitted in Section 7.1 hereof and the definition of “Permitted Liens” herein. 
 7.6 Maintenance of Collateral Accounts. Maintain any Collateral Account, except pursuant to the terms of Section 6.6(b) hereof. 

7.7 Distributions; Investments. (a) Pay any dividends (other than dividends payable solely in common stock) or make any
distribution or payment on or redeem, retire or purchase any capital stock (other than repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements or similar plans), or (b) directly or indirectly
make any Investment other than Permitted Investments, or permit any of its Subsidiaries to do so. 
 7.8 Transactions with
Affiliates. Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower, except for transactions that are in the Ordinary Course of Business, upon fair and reasonable terms that are no less
favorable to Borrower than would be obtained in an arm’s length transaction with a non-affiliated Person. 
 7.9
[Reserved]. 
 7.10 Compliance. Become an “investment company” or a company controlled by an “investment
company”, under the Investment Company Act of 1940, as amended or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve
System), or use the proceeds of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair
Labor Standards Act or violate any other Law or regulation, if the violation could reasonably be expected to result in a Material Adverse Change, or permit any of its Subsidiaries to do so; withdraw or permit any Subsidiary to withdraw from
participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result in any
liability of Borrower, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. 

  
 14 

 7.11 Compliance with Anti-Terrorism Laws. Agent hereby notifies Borrower that
pursuant to the requirements of Anti-Terrorism Laws, and Agent’s policies and practices, Agent is required to obtain, verify and record certain information and documentation that identifies Borrower and its principals, which information
includes the name and address of Borrower and its principals and such other information that will allow Agent to identify such party in accordance with Anti-Terrorism Laws. Borrower will not, nor will Borrower permit any Subsidiary or Affiliate to,
directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists. Borrower shall immediately notify Agent if Borrower has knowledge that Borrower or any Subsidiary or Affiliate
is listed on the OFAC Lists or (a) is convicted on, (b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.
Borrower will not, nor will Borrower permit any Subsidiary or Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving
of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order
No. 13224, any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the
prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law. 
  

	 	8.	EVENTS OF DEFAULT 

Any one of the following shall constitute an event of default (an “Event of Default”) under this Agreement: 

8.1 Payment Default. Borrower fails to (a) make any payment of principal or interest on any Credit Extension on its due date,
or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of acceleration
pursuant to Section 9.1 (a) hereof). During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be made during the cure period); 

8.2 Covenant Default. 
 (a) Borrower fails or neglects to perform any obligation in Sections 6.1(c), 6.2, 6.4, 6.5, 6.6, 6.7, 6.10, 6.11 or 6.12 or violates any covenant in Section 7; or 

(b) Borrower or any of its Subsidiaries fails or neglects to perform, keep, or observe any other term, provision,
condition, covenant or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term, provision, condition, covenant or agreement that can be cured, has
failed to cure the default within twenty (20) days after the occurrence thereof; provided, however, that if the default cannot by its nature be cured within the twenty (20) day period or cannot after diligent attempts by Borrower be
cured within such twenty (20) day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default,
and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period). Grace periods provided under this Section shall not apply, among other
things, to any covenant set forth in subsection (a) above; 
 8.3 Material Adverse Change. A Material Adverse Change
occurs; 
 8.4 Attachment; Levy; Restraint on Business. 

(a) (i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or of any entity
under control of Borrower (including a Subsidiary) on deposit with the Lenders or any Lender Affiliate, or (ii) a notice of lien, levy, or assessment is filed against any of Borrower’s assets by any government agency, and the same under
subclauses (i) and (ii) hereof are not, within ten (10) days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise); provided, however, no Credit Extensions shall be made during
any ten (10) day cure period; and 

  
 15 

 (b) (i) any material portion of Borrower’s assets is attached, seized,
levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower from conducting any material portion of its business; 

8.5 Insolvency. (a) Borrower is unable to pay its debts (including trade debts) as they become due or otherwise becomes
insolvent; (b) Borrower begins an Insolvency Proceeding; or (c) an Insolvency Proceeding is begun against Borrower and not dismissed or stayed within thirty (30) days (but no Credit Extensions shall be made while any of the conditions
described in clause (a) exist and/or until any Insolvency Proceeding is dismissed); 
 8.6 Other Agreements. There
is a default in any agreement to which Borrower is a party with a third party or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of Two
Hundred Fifty Thousand Dollars ($250,000) or that could reasonably be expected to result in a Material Adverse Change and such default has not been waived in writing by such third party or parties; 

8.7 Judgments. One or more judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate,
of at least One Hundred Thousand Dollars ($100,000) (not covered by independent third-party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against Borrower and shall remain unsatisfied, unvacated, or
unstayed for a period of fifteen (15) days after the entry thereof, provided, however, that no Credit Extensions will be made prior to the satisfaction, vacation, or stay of such judgment, order or decree; 

8.8 Misrepresentations. Borrower or any Person acting for Borrower makes any representation, warranty, or other statement now or
later in this Agreement, any Loan Document or in any writing delivered to Agent and/or the Lenders or to induce Agent and/or the Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect
in any material respect when made; 
 8.9 [Reserved]; 
 8.10 Governmental Approvals. Any Governmental Approval shall have been (a) revoked, rescinded, suspended, modified in an adverse manner or not renewed in the Ordinary Course of Business for a
full term, or (b) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications for renewal of any of such Governmental Approval or that could result in the Governmental Authority taking any of
the actions described in clause (a) above, and such decision or such revocation, rescission, suspension, modification or non-renewal (i) has resulted in, or could reasonably be expected to result in, a Material Adverse Change, or
(ii) adversely affects the legal qualifications of Borrower or any of its Subsidiaries to hold such Governmental Approval in any applicable jurisdiction and such revocation, rescission, suspension, modification or non-renewal could reasonably
be expected to affect the status of or legal qualifications of Borrower or any of its Subsidiaries to hold any Governmental Approval in any other jurisdiction; 
 8.11 Criminal Proceeding. The institution by any Governmental Authority of criminal proceedings against Borrower either (a) involving fraud, moral turpitude, or a felony, or (b) that
could reasonably be expected to result in a Material Adverse Change; 
 8.12 Lien Priority. Except as permitted by Agent,
any Lien created hereunder or by any other Loan Document shall at any time fail to constitute a valid and perfected Lien on all of the Collateral purported to be secured thereby, subject to no prior or equal Lien; 

8.13 Change in Control. A Change in Control shall have occurred; or 

8.14 Withdrawals, Recalls, Adverse Test Results and Other Matters. The institution of any proceeding by FDA or similar
Governmental Authority to order the withdrawal of any Sale Compound from the market due to defects in the market or to enjoin Borrower or any representative of Borrower from manufacturing, marketing, selling or distributing any Sale Compound, which,
in each case, could reasonably be expected to result 

  
 16 

 
in a Material Adverse Change, (b) the institution of any action or proceeding by any DEA, FDA, or any other Governmental Authority to revoke, suspend, reject, withdraw, limit, or restrict
any Required Permit held by Borrower or any representative of Borrower, which, in each case, could reasonably be expected to result in a Material Adverse Change, (c) the commencement of any enforcement action against Borrower by DEA, FDA, or
any other Governmental Authority; (d) the recall of any Sale Compound from the market, the voluntary withdrawal of any Sale Compound from the market, or actions to discontinue the sale of any Sale Compound, which in each case could reasonably
be expected to result in a Material Adverse Change, or (e) the occurrence of serious adverse test results related to the safety or efficacy of a Development Compound resulting in the termination of all clinical studies for such Development
Compound which could reasonably be expected to result in a Material Adverse Change. 
  

	 	9.	RIGHTS AND REMEDIES 

9.1 Rights and Remedies. 
 (a) Upon the occurrence and during the continuance of an Event of Default, Agent may, and at the written direction of the Required Lenders shall, without notice or demand, do any or all of the following:
(i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations shall be immediately
due and payable without any action by Agent or the Lenders), or (iii) by notice to Borrower suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under
any other agreement between Borrower and Agent and/or the Lenders (but if an Event of Default described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for Borrower’s benefit under this
Agreement or under any other agreement between Borrower and Agent and/or the Lenders shall be immediately terminated without any action by Agent or the Lenders). 
 (b) Without limiting the rights of Agent and Lenders set forth in Section 9.1(a) above, upon the occurrence and during the continuance of an Event of Default Agent shall have the right, at the
written direction of the Required Lenders, without notice or demand, to do any or all of the following: 
 (i) foreclose upon
and/or sell or otherwise liquidate, the Collateral; 
 (ii) apply to the Obligations any (a) balances and deposits of
Borrower that Agent or any Lender holds or controls, or (b) any amount held or controlled by Agent or any Lender owing to or for the credit or the account of Borrower; and/or 

(iii) commence and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding. 

(c) Without limiting the rights of Agent and Lenders set forth in Sections 9.1(a) and (b) above, upon the occurrence and during the
continuance of an Event of Default Agent shall have the right, without notice or demand, to do any or all of the following: 

(i) settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Agent considers
advisable, notify any Person owing Borrower money of Agent’s security interest in such funds, and verify the amount of such Account; 
 (ii) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the Collateral. Borrower shall assemble the Collateral if Agent
requests and make it available as Agent designates. Agent may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or
superior to its security interest and pay all expenses incurred. Borrower grants Agent a license to enter and occupy any of its premises, without charge, to exercise any of Agent’s rights or remedies; 

  
 17 

 (iii) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or
advertise for sale, the Collateral. Agent is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower’s labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names,
trademarks, service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Agent’s exercise of its rights
under this Section 9.1, Borrower’s rights under all licenses and all franchise agreements inure to Agent for the benefit of the Lenders; 
 (iv) place a “hold” on any account maintained with Agent or the Lenders and/or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any
Control Agreement or similar agreements providing control of any Collateral; 
 (v) demand and receive possession of
Borrower’s Books; and 
 (vi) subject to clauses 9.1(a) and (b), exercise all rights and remedies available to Agent under
the Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof). 
 Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of Default, Agent shall have the right to exercise any and all remedies referenced in this
Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance. As used in the immediately preceding sentence, “Exigent Circumstance” means any event or circumstance that, in the
reasonable judgment of Agent, imminently threatens the ability of Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material
waste thereof, or failure of Borrower after reasonable demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Agent, could result in a material diminution in value of the Collateral. 

9.2 Power of Attorney. Borrower hereby irrevocably appoints Agent as its lawful attorney-in-fact, exercisable upon the occurrence
and during the continuance of an Event of Default, to: (a) endorse Borrower’s name on any checks or other forms of payment or security; (b) sign Borrower’s name on any invoice or bill of lading for any Account or drafts against
Account Debtors; (c) settle and adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms Agent determines reasonable; (d) make, settle, and adjust all claims under Borrower’s insurance
policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and
(f) transfer the Collateral into the name of Agent or a third party as the Code permits. Borrower hereby appoints Agent as its lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue the perfection
of Agent’s security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations have been satisfied in full and Agent and the Lenders are under no further obligation to make Credit Extensions
hereunder. Agent’s foregoing appointment as Borrower’s attorney in fact, and all of Agent’s rights and powers, coupled with an interest, are irrevocable until all Obligations have been fully repaid and performed and Agent’s and
the Lenders’ obligation to provide Credit Extensions terminates. 
 9.3 Protective Payments. If Borrower fails to
obtain the insurance called for by Section 6.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower is obligated to pay under this Agreement or any other Loan Document, Agent may obtain such insurance or make such
payment, and all amounts so paid by Agent are Lenders’ Expenses and immediately due and payable, bearing interest at the then highest applicable rate, and secured by the Collateral. Agent will make reasonable efforts to provide Borrower with
notice of Agent obtaining such insurance at the time it is obtained or within a reasonable time thereafter. No such payments by Agent are deemed an agreement to make similar payments in the future or Agent’s waiver of any Event of Default.

 9.4 Application of Payments and Proceeds. Notwithstanding anything to the contrary contained in this Agreement, upon
the occurrence and during the continuance of an Event of Default, (a) Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Agent from or on behalf of Borrower of all
or any part of the Obligations, and, as between Borrower on the one hand and 

  
 18 

 
Agent and Lenders on the other, Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Agent may deem
advisable notwithstanding any previous application by Agent, and (b) the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied: first, to the Lenders Expenses; second, to accrued and unpaid
interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts); third, to the principal amount of the Obligations outstanding; and fourth, to any other
indebtedness or obligations of Borrower owing to Agent or any Lender under the Loan Documents. Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent
jurisdiction may direct. In carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to
receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category. Any reference in this Agreement to an allocation between or sharing by the
Lenders of any right, interest or obligation “ratably,” “proportionally” or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise. Agent, or if applicable, each Lender, shall promptly remit to the
other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender’s portion of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by Borrower. Notwithstanding the foregoing, a
Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however, if it is later determined that a Lender received more than its
ratable share of scheduled payments made on any date or dates, then such Lender shall remit to the Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Agent. Any payment or
distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender’s ratable share shall be
received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the payments of amounts due on the other Lender’s claims. To the extent any payment for the account of Borrower is required to be
returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis. If any Lender shall obtain possession of any Collateral, it shall hold such
Collateral for itself and as agent and bailee for the Agent and other Lenders for purposes of perfecting Agent’s security interest therein. Notwithstanding anything to the contrary herein, any warrants issued to the Lenders by Borrower, the
stock issuable thereunder, any equity securities purchased by Lenders, any amounts paid thereunder, any dividends, and any other rights in connection therewith shall not be subject to the terms and conditions of this Agreement. Nothing herein shall
affect any Lender’s rights under any such warrants, stock, or other equity securities to administer, manage, transfer, assign, or exercise such warrants, stock, or other equity securities for its own account. 

9.5 Liability for Collateral. So long as Agent and the Lenders comply with reasonable banking practices regarding the safekeeping
of the Collateral in the possession or under the control of Agent and the Lenders, Agent and the Lenders shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any
diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person. Borrower bears all risk of loss, damage or destruction of the Collateral. 

9.6 No Waiver; Remedies Cumulative. Agent’s failure, at any time or times, to require strict performance by Borrower of any
provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Agent thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by
Agent and then is only effective for the specific instance and purpose for which it is given. Agent’s rights and remedies under this Agreement and the other Loan Documents are cumulative. Agent has all rights and remedies provided under the
Code, by Law, or in equity. Agent’s exercise of one right or remedy is not an election, and Agent’s waiver of any Event of Default is not a continuing waiver. Agent’s delay in exercising any remedy is not a waiver, election, or
acquiescence. 
 9.7 Demand Waiver. Borrower waives demand, notice of default or dishonor, notice of payment and
nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Agent on which Borrower is liable. 

  
 19 

 9.8 Borrower Liability. Any Borrower may, acting singly, request Term Loans
hereunder. Each Borrower hereby appoints the others as agent for the others for all purposes hereunder, including with respect to requesting Term Loans hereunder. Each Borrower hereunder shall be jointly and severally obligated to repay all
Term Loans made hereunder and all other Obligations, regardless of which Borrower actually receives said Term Loans, as if each Borrower hereunder directly received all Term Loans. Each Borrower waives (a) any suretyship defenses available
to it under the Code or any other applicable law, and (b) any right to require the Lenders or Agent to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other
remedy. The Lenders or Agent may exercise or not exercise any right or remedy they have against any Borrower or any security (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower’s
liability. Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the
rights of the Lenders and Agent under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations,
for any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made
by Borrower with respect to the Obligations in connection with this Agreement or otherwise. Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void. If any
payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for the Lenders and Agent and such payment shall be promptly delivered to Agent for application to the Obligations, whether matured or
unmatured. 
  

	 	10.	NOTICES 

 All
notices, consents, requests, approvals, demands, or other communication (collectively, “Communication”) by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served,
given, or delivered: (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b) upon
transmission, when sent by electronic mail (if an email address is specified herein) or facsimile transmission; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid; or (d) when delivered,
if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Any of Agent, Lender or Borrower may change its mailing or electronic mail
address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Section 10. 
 If to any Borrower: 
 Furiex Pharmaceuticals, Inc. 

3900 Paramount Parkway, Suite 150 
 Morrisville, North Carolina 27560 
 Attention: President and Chief Financial
Officer 
 Fax: (919) 456-7850 
 E-Mail:    June.Almenoff@furiex.com 

        Marshall.Woodworth@furiex.com 

If to Agent: 
 MidCap Funding III, LLC 
 7255 Woodmont Avenue, Suite 200 

Bethesda, Maryland 20814 
 Attention: Portfolio Management- Life Sciences 
 Fax: (301) 941-1450

 E-Mail:  Lviera@midcapfinancial.com 
 with a copy to: 

  
 20 

 Midcap Financial, LLC 

7255 Woodmont Avenue, Suite 200 
 Bethesda, Maryland 20814 
 Attention: General Counsel 

Fax: (301) 941-1450 
 E-Mail:  Rgoodridge@midcapfinancial.com 
 If to
Lenders:  To the address specified on the signature page of such Lender attached hereto. 

  
 21 

	 	11.	CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER 

 THIS AGREEMENT, EACH SECURED PROMISSORY NOTE AND EACH OTHER LOAN DOCUMENT, AND ALL MATTERS RELATING HERETO OR THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL
BE GOVERNED BY, AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF MARYLAND, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES. NOTWITHSTANDING THE FOREGOING, AGENT AND LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR
PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH AGENT AND LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 9.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE
AGENT’S AND LENDERS’ RIGHTS AGAINST BORROWER OR ITS PROPERTY. BORROWER EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND BORROWER HEREBY WAIVES ANY OBJECTION THAT IT MAY
HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE, OR FORUM NON CONVENIENS AND HEREBY CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT. BORROWER HEREBY WAIVES PERSONAL SERVICE OF THE
SUMMONS, COMPLAINTS, AND OTHER PROCESS ISSUED IN SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINTS, AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO BORROWER AT THE ADDRESS SET FORTH IN SECTION 10
OF THIS AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER TO OCCUR OF BORROWER’S ACTUAL RECEIPT THEREOF OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID. 

TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, AGENT AND LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR
CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS
AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL. 
 Borrower, Agent and each Lender agree that each Term
Loan (including those made on the Closing Date) shall be deemed to be made in, and the transactions contemplated hereunder and in any other Loan Document shall be deemed to have been performed in, the State of Maryland. 

 

	 	12.	GENERAL PROVISIONS 

12.1 Successors and Assigns. This Agreement binds and is for the benefit of the successors and permitted assigns of each party.
Borrower may not assign this Agreement or any rights or obligations under it without Agent’s prior written consent (which may be granted or withheld in Agent’s discretion). Any Lender may at any time assign to one or more Eligible
Assignees all or any portion of such Lender’s Loan, together with all related obligations of such Lender hereunder. Borrower and Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests
so assigned until Agent shall have received and accepted an effective assignment agreement in form and substance acceptable to Agent, executed, delivered and fully completed by the applicable parties thereto, and shall have received such other
information regarding such Eligible Assignee as Agent reasonably shall require. Notwithstanding anything set forth in this Agreement to the contrary, any Lender may at any time pledge or assign a security interest in all or any portion of its rights
under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided, however, that no such pledge or assignment shall release such Lender from any of its
obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. 
 12.2
Indemnification. 

  
 22 

 (a) Borrower agrees to indemnify, defend and hold Agent and the Lenders and
their respective directors, officers, employees, agents, attorneys, or any other Person affiliated with or representing Agent or the Lenders (each, an “Indemnified Person”) harmless against: (i) all obligations, demands,
claims, and liabilities (collectively, “Claims”) asserted by any other party in connection with the transactions contemplated by the Loan Documents; and (ii) all losses or Lenders’ Expenses incurred, or paid by Indemnified
Person from, following, or arising from transactions between Agent, and/or the Lenders and Borrower (including reasonable attorneys’ fees and expenses) pursuant to or in connection with the Loan Documents, except for Claims and/or losses
directly caused by such Indemnified Person’s gross negligence or willful misconduct (collectively, the “Indemnified Liabilities”). 
 (b) Borrower hereby further indemnifies, defends and holds each Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits,
claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnitee) in connection with any investigative, response, remedial, administrative or judicial matter or
proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and
similar technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred
by or asserted against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds. 

(c) To the extent that the undertaking set forth in this Section 12.2 may be unenforceable, Borrower shall contribute
the maximum portion which it is permitted to pay and satisfy under applicable law to the payment and satisfaction of all such indemnified liabilities incurred by the Indemnitees or any of them. 

12.3 Time of Essence. Time is of the essence for the performance of all Obligations in this Agreement. 

12.4 Severability of Provisions. Each provision of this Agreement is severable from every other provision in determining the
enforceability of any provision. 
 12.5 Correction of Loan Documents. Agent and the Lenders may correct patent errors
and fill in any blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties. 
 12.6
Integration. This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations
between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents. 
 12.7 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and
all taken together, constitute one Agreement. 
 12.8 Survival. All covenants, representations and warranties made in
this Agreement continue in full force until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this
Agreement) have been satisfied. The obligation of Borrower in Section 12.2 to indemnify each Lender and Agent shall survive until the statute of limitations with respect to such claim or cause of action shall have run. 

12.9 Confidentiality. In handling any confidential information of Borrower, the Lenders and Agent shall exercise the same degree
of care that it exercises for its own proprietary information, but disclosure of information may be made: (a) to the Lenders’ and Agent’s Subsidiaries or Affiliates; (b) to prospective transferees or purchasers of any interest in
the Credit Extensions (provided, however, the Lenders and Agent shall use commercially reasonable efforts to obtain such prospective transferee’s or purchaser’s agreement to the terms of this provision); (c) as required by Law,
regulation, subpoena, or other order; (d) to regulators or as otherwise required in 

  
 23 

 
connection with an examination or audit; (e) as Agent considers appropriate in exercising remedies under the Loan Documents; and (f) to third party service providers of the Lenders
and/or Agent so long as such service providers have executed a confidentiality agreement with the Lenders and Agent with terms no less restrictive than those contained herein. Confidential information does not include information that either:
(i) is in the public domain or in the Lenders’ and/or Agent’s possession when disclosed to the Lenders and/or Agent, or becomes part of the public domain after disclosure to the Lenders and/or Agent; or (ii) is disclosed to the
Lenders and/or Agent by a third party, if the Lenders and/or Agent does not know that the third party is prohibited from disclosing the information. Agent and/or Lenders may use confidential information for any purpose, including, without
limitation, for the development of client databases, reporting purposes, and market analysis, so long as Agent and/or Lenders, as applicable, do not disclose Borrower’s identity or the identity of any Person associated with Borrower unless
otherwise expressly permitted by this Agreement. The provisions of the immediately preceding sentence shall survive the termination of this Agreement. The agreements provided under this Section 12.9 supersede all prior agreements,
understanding, representations, warranties, and negotiations between the parties about the subject matter of this Section 12.9. 
 12.10 Right of Set Off. Borrower hereby grants to Agent and to each Lender, a lien, security interest and right of set off as security for all Obligations to Agent and each Lender hereunder,
whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Agent or the Lenders or any entity under the control of Agent or the
Lenders (including a Agent affiliate) or in transit to any of them. At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Agent or the Lenders may set off the same or any part thereof and apply
the same to any liability or obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY
OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED. 

12.11 [Reserved.] 
 12.12 Amendments. 
 (a) No amendment, modification,
termination or waiver of any provision of this Agreement or any other Loan Document, nor approval or consent thereunder, or any consent to any departure by Borrower therefrom, shall in any event be effective unless the same shall be in writing and
signed by Borrower, Agent and the Required Lenders, provided, however, that 
 (i) no such amendment,
waiver or other modification that would have the effect of increasing or reducing a Lender’s Term Loan Commitment or Commitment Percentage shall be effective as to such Lender without such Lender’s written consent; 

(ii) no such amendment, waiver or modification that would affect the rights and duties of Agent shall be effective without
Agent’s written consent or signature; 
 (iii) no such amendment, waiver or other modification shall, unless
signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees (other than late charges)
with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges or for
any termination of any commitment); (C) change the definition of the term “Required Lenders” or the percentage of Lenders which shall be required for Lenders to take any action hereunder; (D) release all or substantially all or
any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty
obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder);
(E) amend, waive or otherwise modify this Section 12.12 or the definitions of the terms used in this Section 12.12 insofar as the definitions affect the substance of this Section 12.12; (F) consent to the assignment,
delegation or 

  
 24 

 
other transfer by any Borrower or any Guarantor of any of its rights and obligations under any Loan Document or release Borrower or any Guarantor of its payment obligations under any Loan
Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement; (G) amend any of the provisions of Section 9.4 or amend any of the definitions Pro Rata Share, Term
Loan Commitment, Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral hereunder; (H) subordinate the Liens granted in favor of Agent securing the
Obligations; or (I) amend any of the provisions of Section 12.10. It is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding
clauses (C), (D), (E), (F), (G) and (H) of the preceding sentence; 
 (iv) the provisions of the
foregoing clauses (i), (ii) and (iii) are subject to the provisions of any interlender or agency agreement among the Agent and Lenders pursuant to which any Lender may agree to give its consent in connection with any amendment, waiver or
modification of the Loan Documents only in the event of the unanimous agreement of all Lenders. 
 (b) Other than
as expressly provided for in Section 12.12(a)(i) through (iii) above, Agent may, if requested by the Required Lenders, from time to time designate covenants in this Agreement less restrictive by notification to a representative
of the Borrower. 
 12.13 Publicity. Borrower will not directly or indirectly publish, disclose or otherwise use in any
public disclosure, advertising material, promotional material, press release or interview, any reference to the name, logo or any trademark of Agent or any Lender or any of their Affiliates or any reference to this Agreement or the financing
evidenced hereby, in any case except as required by applicable Law, subpoena or judicial or similar order, in which case Borrower shall endeavor to give Agent prior written notice of such publication or other disclosure; provided,
however, that for the avoidance of doubt, Borrower may publish the name of Lenders and Agent, the existence of the financing arrangements referenced under this Agreement, the primary purpose and/or structure of those arrangements, the amount
of credit extended under each facility, the title and role of each party to this Agreement, and the total amount of financing evidenced hereby and such other information (including copies of the Loan Documents) necessary to satisfy the reporting
requirements under the Securities Exchange Act of 1934, as amended. Each Lender and Borrower hereby authorizes each Lender to publish the name of such Lender and Borrower, the existence of the financing arrangements referenced under this Agreement,
the primary purpose and/or structure of those arrangements, the amount of credit extended under each facility, the title and role of each party to this Agreement, and the total amount of the financing evidenced hereby in any “tombstone”,
comparable advertisement or press release which such Lender elects to submit for publication. In addition, each Lender and Borrower agrees that each Lender may provide lending industry trade organizations with information necessary and customary for
inclusion in league table measurements after the Closing Date. With respect to any of the foregoing authorizations granted to Lenders, such authorization shall be subject to such Lender providing Borrower and the other Lenders with an opportunity to
review and confer with such Lender regarding, and approve, the contents of any such tombstone, advertisement or information, as applicable, prior to its initial submission for publication, but subsequent publications of the same tombstone,
advertisement or information shall not require Borrower’s approval. 
 12.14 No Strict Construction. The
parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and
no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
  

	 	13.	AGENT 

 13.1
Appointment and Authorization of Agent. Each Lender hereby irrevocably appoints, designates and authorizes Agent to take such action on its behalf under the provisions of this Agreement and each other Loan Document and to exercise such powers
and perform such duties as are expressly delegated to it by the terms of this Agreement or any other Loan Document, together with such powers as are reasonably incidental thereto. Notwithstanding any provision to the contrary contained elsewhere
herein or in any other Loan Document, Agent shall not have any duties or responsibilities, except those expressly set forth herein, nor shall Agent have or be deemed to have any fiduciary relationship with any Lender or participant, and no implied
covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Loan Document or 

  
 25 

 
otherwise exist against Agent. Without limiting the generality of the foregoing sentence, the use of the term “agent” herein and in the other Loan Documents with reference to Agent is
not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead, such term is used merely as a matter of market custom, and is intended to create or reflect only an
administrative relationship between independent contracting parties. 
 13.2 Delegation of Duties. Agent may execute any
of its duties under this Agreement or any other Loan Document by or through its, or its Affiliates’, agents, employees or attorneys-in-fact and shall be entitled to obtain and rely upon the advice of counsel and other consultants or experts
concerning all matters pertaining to such duties. Agent shall not be responsible for the negligence or misconduct of any agent or attorney-in-fact that it selects in the absence of gross negligence or willful misconduct. 

13.3 Liability of Agent. Except as otherwise provided herein, no Agent-Related Person shall (a) be liable for any action
taken or omitted to be taken by any of them under or in connection with this Agreement or any other Loan Document or the transactions contemplated hereby (except for its own gross negligence or willful misconduct in connection with its duties
expressly set forth herein), or (b) be responsible in any manner to any Lender or participant for any recital, statement, representation or warranty made by Borrower or any officer thereof, contained herein or in any other Loan Document, or in
any certificate, report, statement or other document referred to or provided for in, or received by Agent under or in connection with, this Agreement or any other Loan Document, or the validity, effectiveness, genuineness, enforceability or
sufficiency of this Agreement or any other Loan Document, or for any failure of Borrower or any other party to any Loan Document to perform its obligations hereunder or thereunder. No Agent-Related Person shall be under any obligation to any Lender
or participant to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement or any other Loan Document, or to inspect the properties, books or records of Borrower or any
Affiliate thereof. 
 13.4 Reliance by Agent. Agent shall be entitled to rely, and shall be fully protected in relying,
upon any writing, communication, signature, resolution, representation, notice, consent, certificate, affidavit, letter, telegram, facsimile, telex or telephone message, electronic mail message, statement or other document or conversation believed
by it to be genuine and correct and to have been signed, sent or made by the proper Person or Persons, and upon advice and statements of legal counsel (including counsel to Borrower), independent accountants and other experts selected by Agent.
Agent shall be fully justified in failing or refusing to take any action under any Loan Document unless it shall first receive such advice or concurrence of all Lenders as it deems appropriate and, if it so requests, it shall first be indemnified to
its satisfaction by the Lenders against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action. Agent shall in all cases be fully protected in acting, or in refraining from acting,
under this Agreement or any other Loan Document in accordance with a request or consent of all Lenders and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders. 

13.5 Notice of Default. Agent shall not be deemed to have knowledge or notice of the occurrence of any Default and/or Event of
Default, unless Agent shall have received written notice from a Lender or Borrower, describing such default or Event of Default. Agent will notify the Lenders of its receipt of any such notice. Agent shall take such action with respect to an Event
of Default as may be directed in writing by the Required Lenders in accordance with Section 9(a); provided, however, that while an Event of Default has occurred and is continuing, Agent may (but shall not be obligated to) take such
action, or refrain from taking such action, with respect to such Event of Default as Agent shall deem advisable or in the best interest of the Lenders, including without limitation, satisfaction of other security interests, liens or encumbrances on
the Collateral not permitted under the Loan Documents, payment of taxes on behalf of Borrower, payments to landlords, warehouseman, bailees and other Persons in possession of the Collateral and other actions to protect and safeguard the Collateral,
and actions with respect to insurance claims for casualty events affecting Borrower and/or the Collateral. 
 13.6 Credit
Decision; Disclosure of Information by Agent. Each Lender acknowledges that no Agent-Related Person has made any representation or warranty to it, and that no act by Agent hereafter taken, including any consent to and acceptance of any
assignment or review of the affairs of Borrower or any Affiliate thereof, shall be deemed to constitute any representation or warranty by any Agent-Related Person to any Lender as to any matter, including whether Agent-Related Persons have disclosed
material information in their possession. Each Lender 

  
 26 

 
represents to Agent that it has, independently and without reliance upon any Agent-Related Person and based on such documents and information as it has deemed appropriate, made its own appraisal
of, and investigation into, the business, prospects, operations, property, financial and other condition and creditworthiness of Borrower and its respective Subsidiaries, and all applicable bank or other regulatory Laws relating to the transactions
contemplated hereby, and made its own decision to enter into this Agreement and to extend credit to Borrower hereunder. Each Lender also represents that it will, independently and without reliance upon any Agent-Related Person and based on such
documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Loan Documents, and to make such investigations
as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of Borrower. Except for notices, reports and other documents expressly required to be furnished to the
Lenders by Agent herein, Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects, operations, property, financial and other condition or creditworthiness of
Borrower or any of its Affiliates which may come into the possession of any Agent-Related Person. 
 13.7 Indemnification of
Agent. Whether or not the transactions contemplated hereby are consummated, each Lender shall, severally and pro rata based on its respective Pro Rata Share, indemnify upon demand each Agent-Related Person (to the extent not reimbursed by or on
behalf of Borrower and without limiting the obligation of Borrower to do so), and hold harmless each Agent-Related Person from and against any and all Indemnified Liabilities (which shall not include legal expenses of Agent incurred in connection
with the closing of the transactions contemplated by this Agreement) incurred by it; provided, however, that no Lender shall be liable for the payment to any Agent-Related Person of any portion of such Indemnified Liabilities to the extent
determined in a judgment by a court of competent jurisdiction to have resulted from such Agent-Related Person’s own gross negligence or willful misconduct; provided, however, that no action taken in accordance with the directions of the
Required Lenders shall be deemed to constitute gross negligence or willful misconduct for purposes of this Section 13.7. Without limitation of the foregoing, each Lender shall, severally and pro rata based on its respective Pro Rata Share,
reimburse Agent upon demand for its ratable share of any costs or out-of-pocket expenses (including Lenders’ Expenses incurred after the closing of the transactions contemplated by this Agreement) incurred by Agent (in its capacity as Agent,
and not as a Lender) in connection with the preparation, execution, delivery, administration, modification, amendment or enforcement (whether through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or
responsibilities under, this Agreement, any other Loan Document, or any document contemplated by or referred to herein, to the extent that Agent is not reimbursed for such expenses by or on behalf of Borrower. The undertaking in this
Section 13.7 shall survive the payment in full of the Obligations, the termination of this Agreement and the resignation of Agent. 
 13.8 Agent in its Individual Capacity. With respect to its Credit Extensions, MidCap shall have the same rights and powers under this Agreement as any other Lender and may exercise such rights and
powers as though it were not Agent, and the terms “Lender” and “Lenders” include MidCap in its individual capacity. 
 13.9 Successor Agent. 
 (a) Agent may at any time assign its
rights, powers, privileges and duties hereunder to (i) another Lender, or (ii) any Person to whom Agent, in its capacity as a Lender, has assigned (or will assign, in conjunction with such assignment of agency rights hereunder) 50% or more
of its Loan, in each case without the consent of the Lenders or Borrowers. Following any such assignment, Agent shall give notice to the Lenders and Borrowers. An assignment by Agent pursuant to this subsection (a) shall not be deemed a
resignation by Agent for purposes of subsection (b) below. 
 (b) Without limiting the rights of Agent to
designate an assignee pursuant to subsection (a) above, Agent may at any time give notice of its resignation to the Lenders and Borrowers. Upon receipt of any such notice of resignation, Required Lenders shall have the right to appoint a
successor Agent. If no such successor shall have been so appointed by Required Lenders and shall have accepted such appointment within ten (10) Business Days after the retiring Agent gives notice of its resignation, then the retiring Agent may,
on behalf of the Lenders, appoint a successor Agent; provided, however, that if Agent shall notify Borrowers and the Lenders that no Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance
with such notice from Agent that no Person has accepted such appointment and, from and following delivery of such notice, (i)

  
 27 

 
the retiring Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents, and (ii) all payments, communications and determinations provided to be
made by, to or through Agent shall instead be made by or to each Lender directly, until such time as Required Lenders appoint a successor Agent as provided for above in this subsection (b). 

(c) Upon (i) an assignment permitted by subsection (a) above, or (ii) the acceptance of a successor’s
appointment as Agent pursuant to subsection (b) above, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Agent, and the retiring Agent shall be discharged from
all of its duties and obligations hereunder and under the other Loan Documents (if not already discharged therefrom as provided above in this subsection (c)). The fees payable by Borrowers to a successor Agent shall be the same as those payable to
its predecessor unless otherwise agreed between Borrower and such successor. After the retiring Agent’s resignation hereunder and under the other Loan Documents, the provisions of this Section 13 shall continue in effect for the
benefit of such retiring Agent and its sub-agents in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting or was continuing to act as Agent. 

13.10 Agent May File Proofs of Claim. In case of the pendency of any receivership, insolvency, liquidation, bankruptcy,
reorganization, arrangement, adjustment, composition or other judicial proceeding relative to Borrower, Agent (irrespective of whether the principal of any Loan, shall then be due and payable as herein expressed or by declaration or otherwise and
irrespective of whether Agent shall have made any demand on Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise: 
 (a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Credit Extensions and all other Obligations that are owing and unpaid and to file such
other documents as may be necessary or advisable in order to have the claims of the Lenders and Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and Agent and their respective agents and
counsel and all other amounts due the Lenders and Agent allowed in such judicial proceeding); and 
 (b) to
collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same; 
 and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to Agent and,
in the event that Agent shall consent to the making of such payments directly to the Lenders, to pay to Agent any amount due for the reasonable compensation, expenses, disbursements and advances of Agent and its agents and counsel, and any other
amounts due Agent under Section 2.4(d). To the extent that Agent fails timely to do so, each Lender may file a claim relating to such Lender’s claim. 
 13.11 Collateral and Guaranty Matters. The Lenders irrevocably authorize Agent, at its option and in its discretion, to release any Guarantor and any Lien on any Collateral granted to or held by
Agent under any Loan Document (a) upon the date that all Obligations due hereunder have been fully and indefeasibly paid in full and no Term Loan Commitments or other obligations of any Lender to provide funds to Borrower under this Agreement
remain outstanding, (b) that is transferred or to be transferred as part of or in connection with any Transfer permitted hereunder or under any other Loan Document, or (c) as approved in accordance with Section 12.12. Upon request by
Agent at any time, all Lenders will confirm in writing Agent’s authority to release its interest in particular types or items of Property, pursuant to this Section 13.11. 

13.12 Cooperation of Borrower. If necessary, Borrower agrees to (a) execute any documents (including new Secured Promissory
Notes) reasonably required to effectuate and acknowledge each assignment of a Term Loan Commitment or Loan to an assignee in accordance with Section 12.1, (b) make Borrower’s management available to meet with Agent and prospective
participants and assignees of Term Loan Commitments or Credit Extensions and (c) assist Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of a Term
Loan Commitment or Term Loan reasonably may request. Subject to the provisions of Section 12.9 Borrower authorizes each Lender to disclose to any prospective 

  
 28 

 
participant or assignee of a Term Loan Commitment, any and all information in such Lender’s possession concerning Borrower and its financial affairs which has been delivered to such Lender
by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender’s credit evaluation of Borrower prior to entering into this Agreement. 

 

	 	14.	DEFINITIONS 

 As
used in this Agreement, the following terms have the following meanings: 
 “Account” means any
“account”, as defined in the Code, with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower. 

“Account Debtor” means any “account debtor”, as defined in the Code, with such additions to such term as may
hereafter be made. 
 “Affiliate” means, with respect to any Person, a Person that owns or controls directly or
indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and, for any Person that is a limited liability company,
that Person’s managers and members. 
 “Agent” means, MidCap, not in its individual capacity, but solely
in its capacity as agent on behalf of and for the benefit of the Lenders. 
 “Agent-Related Person” means the
Agent, together with its Affiliates, and the officers, directors, employees, agents, advisors, auditors and attorneys-in-fact of such Persons; provided, however, that no Agent-Related Person shall be an Affiliate of Borrower. 

“Agreement” has the meaning given it in the preamble of this Agreement. 

“Amortization Date” means (a) with respect to the Tranche One Term Loan, August 1, 2012 and (b) with
respect to the Tranche Two Term Loan, the first Payment Date that occurs twelve (12) months after the advance of such Tranche Two Term Loan. 
 “Anti-Terrorism Laws” means any Laws relating to terrorism or money laundering, including Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the Laws
comprising or implementing the Bank Secrecy Act, and the Laws administered by OFAC. 
 “Approved Drug” has the
meaning given it in the definition of “Sale Compound”. 
 “Approved Fund” means any
(a) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the Ordinary Course of Business,
or (b) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding clause (a) and that, with respect to each of the preceding clauses (a) and (b), is administered
or managed by (i) a Lender, (ii) an Affiliate of a Lender or (iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender. 

“Base LIBOR Rate” means, for any Interest Period, the rate per annum, determined by Agent in accordance with its
customary procedures, and utilizing such electronic or other quotation sources as it considers appropriate (rounded upwards, if necessary, to the next 1/100th%), to be the rate at which Dollar deposits (for delivery on the first day of such Interest
Period or, if such day is not a Business Day, on the preceding Business Day) in the amount of One Million Dollars ($1,000,000) are offered to major banks in the London interbank market on or about 11:00 a.m. (New York time) two (2) Business
Days prior to the commencement of such Interest Period, for a term comparable to such Interest Period, which determination shall be conclusive in the absence of manifest error. 

  
 29 

 “Blocked Person” means: (a) any Person listed in the annex to,
or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive
Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports
“terrorism” as defined in Executive Order No. 13224, or (e) a Person that is named a “specially designated national” or “blocked person” on the most current list published by OFAC or other similar list.

 “Borrower” has the meaning given it in the preamble of this Agreement. 

“Borrower’s Books” means all of Borrower’s books and records, including ledgers, federal and state tax
returns, records regarding Borrower’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information. 

“Borrowing Resolutions” means, with respect to any Person, those resolutions adopted by such Person’s Board of
Directors or other governing body whose approval is necessary or desired by Borrower or Agent and delivered by such Person to Agent approving the Loan Documents to which such Person is a party and the transactions contemplated thereby, together with
a certificate executed by its secretary on behalf of such Person certifying that (a) such Person has the authority to execute, deliver, and perform its obligations under each of the Loan Documents to which it is a party, (b) that attached
as Exhibit A to such certificate is a true, correct, and complete copy of the resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Person of the Loan Documents to which it is a party,
(c) the name(s) of the Person(s) authorized to execute the Loan Documents on behalf of such Person, together with a sample of the true signature(s) of such Person(s), and (d) that Agent and the Lenders may conclusively rely on such
certificate unless and until such Person shall have delivered to Agent a further certificate canceling or amending such prior certificate. 
 “Business Day” means any day that is not a Saturday, Sunday or a day on which Agent is closed for business. 
 “Cash Equivalents” means (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more
than one (1) year from the date of acquisition, (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s
Investors Service, Inc., (c) certificates of deposit issued maturing no more than one (1) year after issue, and (d) money market funds at least ninety-five percent (95%) of the assets of which constitute Cash Equivalents of the
kinds described in clauses (a) through (b) of this definition. For the avoidance of doubt, the direct purchase by Borrower, co-borrower, or any subsidiary of Borrower of any Auction Rate Securities, or purchasing participations in, or
entering into any type of swap or other derivative transaction, or otherwise holding or engaging in any ownership interest in any type of Auction Rate Security by Borrower, co-borrower, or any subsidiary of Borrower shall be conclusively determined
by the Lenders as an ineligible Cash Equivalent, and any such transaction shall expressly violate each other provision of this agreement governing Permitted Investments. Notwithstanding the foregoing, Cash Equivalents does not include, and each
Borrower and Subsidiary is prohibited from purchasing, purchasing participations in, entering into any type of swap or other equivalent derivative transaction, or otherwise holding or engaging in any ownership interest in any type of debt
instrument, including, without limitation, any corporate or municipal bonds with a long-term nominal maturity for which the interest rate is reset through a dutch auction and more commonly referred to as an auction rate security. 

“Change in Control” means any event, transaction, or occurrence as a result of which (a) any “person” (as
such term is defined in Sections 3(a)(9) and 13(d)(3) of the Exchange Act), other than (i) a trustee or other fiduciary holding securities under an employee benefit plan of Borrower or (ii) Fred Eshelman, is or becomes, or has entered into
a contract which upon consummation shall make such person, a beneficial owner (within the meaning Rule 13d-3 promulgated under the Exchange Act), directly or indirectly, of securities of Borrower, representing forty percent (40%) or more of the
combined voting power of Borrower’s then outstanding securities; (b) any Borrower ceases to own, directly or indirectly, (100%) of the capital stock of any of its Subsidiaries; or (c) during any period of twelve consecutive
calendar months, individuals who at the beginning of such period constituted the Board of Directors of Borrower (together with any new directors whose election by the Board of Directors of Borrower was approved by a vote of not less than two-thirds
of the directors then still in office who either were directors at the beginning of such 

  
 30 

 
period or whose election or nomination for election was previously so approved) cease for any reason other than death or disability to constitute a majority of the directors then in office.

 “Claims” has the meaning given it in Section 12.2. 

“Closing Date” has the meaning given it in the preamble of this Agreement. 

“Code” means the Uniform Commercial Code in effect on the date hereof, as the same may, from time to time, be enacted
and in effect in the State of Maryland; provided, however, that to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the
definition of such term contained in Article or Division 9 shall govern; and provided, further, that in the event that, by reason of mandatory provisions of Law, any or all of the attachment, perfection, or priority of, or remedies with
respect to, Agent’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of Maryland, the term “Code” shall mean the Uniform Commercial Code as enacted and in effect
in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions. 

“Collateral” means all property, now existing or hereafter acquired, mortgaged or pledged to, or purported to be
subjected to a Lien in favor of Agent, for the benefit of Agent and Lenders, pursuant to this Agreement and the other Loan Documents, including, without limitation, all of the property described in Exhibit A hereto. 

“Collateral Account” means any Deposit Account, Securities Account or Commodity Account. 

“Commitment Percentage” means, as to any Lender, the percentage set forth opposite such Lender’s name on
Schedule 1, as amended from time to time. 
 “Commodity Account” means any “commodity
account”, as defined in the Code, with such additions to such term as may hereafter be made. 

“Communication” has the meaning given it in Section 10. 

“Compliance Certificate” means a certificate, duly executed by an authorized officer of Borrower, appropriately
completed and substantially in the form of Exhibit C. 
 “Contingent Obligation” means, for any Person,
any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made,
discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate,
currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent
Obligation” does not include endorsements in the Ordinary Course of Business. The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not
determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. 

“Control Agreement” means any control agreement entered into among the depository institution at which Borrower
maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Agent pursuant to which Agent obtains control (within the meaning of the
Code) for the benefit of the Lenders over such Deposit Account, Securities Account or Commodity Account. 
 “Credit
Extension” means any Term Loan or any other extension of credit by Agent or the Lenders for Borrower’s benefit. 

  
 31 

 “DEA” means the Drug Enforcement Administration of the United States of
America, and any successor agency thereof. 
 “Default” means any event which with notice or passage of time or
both, would constitute an Event of Default. 
 “Default Rate” has the meaning given it in Section 2.3(c).

 “Deposit Account” means any “deposit account” as defined in the Code with such additions to such
term as may hereafter be made. 
 “Designated Deposit Account” means Borrower’s deposit account, account
number [*], maintained with Silicon Valley Bank and over which Agent has been granted control for the ratable benefit of the Lenders. 
 “Development Compound” means any therapeutic compound being tested by any Borrower or any of its Subsidiaries, including without limitation, those drug compounds set forth on Schedule
5.11, for use in Phase I, Phase II or Phase III trials. 
 “Development Inventory” means the
Borrower’s inventory of Development Compounds. 
 “Dollars,” “dollars” and
“$” each means lawful money of the United States. 
 “Draw Period” means the period of time
commencing upon the Closing Date and continuing through the earliest to occur of (a) the Draw Period Termination Date, (b) an Event of Default, and (c) the existence of any Default. 

“Draw Period Termination Date” means March 31, 2012. 

“Drug Application” means a new drug application, an abbreviated drug application, or a product license application for
any Product, as appropriate, as those terms are defined in the FDCA. 
 “Eligible Assignee” means (a) a
Lender, (b) an Affiliate of a Lender, (c) an Approved Fund, and (d) any other Person (other than a natural person) approved by Agent; provided, however, that notwithstanding the foregoing, “Eligible Assignee” shall
not include Borrower, any Guarantor or any of Borrower’s or any Guarantor’s Affiliates or Subsidiaries. Notwithstanding the foregoing, in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory
agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party becoming an assignee incident to such forced divestiture. 
 “Equipment” means all “equipment”, as defined in the Code, with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures,
goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. 
 “ERISA”
means the Employee Retirement Income Security Act of 1974, and all regulations promulgated thereunder. 
 “Event of
Default” has the meaning given it in Section 8. 
 “FDA” means the Food and Drug Administration
of the United States of America, or any successor entity thereto. 
 “FDCA” means the Federal Food, Drug and
Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq., and all regulations promulgated thereunder. 

  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 32 

 “Final Payment” means a payment (in addition to and not a substitution for
the regular monthly payments of principal plus accrued interest) due on the earlier to occur of (a) the Maturity Date, (b) the acceleration of any Term Loan, and (c) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d), equal to the Term
Loan Commitments multiplied by the Final Payment Percentage. 
 “Final Payment Percentage” means two and
one half of one percent (2.5%). 
 “Foreign Subsidiary” means, with respect to any Person, a Subsidiary of such
Person that is a “controlled foreign corporation” under Section 957 of the IRC. 
 “Funding
Date” means any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day. 

“GAAP” means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting
Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of
the accounting profession in the United States, which are applicable to the circumstances as of the date of determination. 

“General Intangibles” means all “general intangibles”, as defined in the Code, with such additions to such
term as may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents,
trademarks, service marks and, to the extent permitted under applicable Law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract
rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights
in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment
of any kind. 
 “Governmental Approval” means any consent, authorization, approval, order, license, franchise,
permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority. 
 “Governmental Authority” means any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or
other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization. 

“Guarantor” means any present or future guarantor of the Obligations. 

“Indebtedness” means (a) indebtedness for borrowed money or the deferred price of property or services, such as
reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, and (d) Contingent Obligations. 

“Indemnified Liabilities” has the meaning given it in Section 12.2. 

“Indemnified Person” has the meaning given it in Section 12.2. 

“Insolvency Proceeding” means any proceeding by or against any Person under the United States Bankruptcy Code, or any
other bankruptcy or insolvency Law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

  
 33 

 “Intellectual Property” includes without limitation, all copyright rights,
copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions,
continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks, trade names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor, whether
registered or not, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing. 

“Interest Period” means the one-month period for each Term Loan commencing on the date that the applicable Term Loan is
made and ending on the last day of such month. 
 “Interest Rate Determination Date” means
the second (2nd) Business Day prior to the Funding
Date for the applicable Term Loan. 
 “Inventory” means all “inventory”, as defined in the Code, with
such additions to such term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory
as is temporarily out of Borrower’s custody or possession or in transit and including any returned goods and any documents of title representing any of the above. 
 “Investment” means any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance or capital contribution to any
Person. 
 “IRC” means the Internal Revenue Code of 1986. 

“Laws” means any and all federal, state, provincial, territorial, local and foreign statutes, laws, judicial decisions,
regulations, guidances, guidelines, ordinances, rules, judgments, orders, decrees, codes, plans, injunctions, permits, concessions, grants, franchises, governmental agreements and governmental restrictions, whether now or hereafter in effect, which
are applicable to any Borrower in any particular circumstance. 
 “Lender” means any one of the Lenders.

 “Lenders” means the Persons identified on Schedule 1 hereto, and each assignee that becomes a party
to this Agreement pursuant to Section 12.1. 
 “Lenders’ Expenses” means all documented,
out-of-pocket due diligence fees and expenses and other fees, costs, and expenses (including reasonable attorneys’ fees and expenses) of Agent and Lenders for preparing, amending, negotiating, administering, defending and enforcing this
Agreement and the other Loan Documents (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred by Agent or the Lenders in connection with the Loan Documents. 

“LIBOR Rate” means, for each Interest Period, the rate per annum determined by Agent (rounded upwards, if necessary, to
the next 1/100th%) by dividing (a) the Base LIBOR Rate for such Interest Period, by (b) 100% minus the Reserve Percentage. The LIBOR Rate shall be adjusted on and as of the effective day of any change in the Reserve Percentage.

 “LIBOR Rate Margin” means seven and one fourth of one percent (7.25%) per annum. 

“Lien” means a claim, mortgage, deed of trust, levy, charge, pledge, security interest or other encumbrance of any kind,
whether voluntarily incurred or arising by operation of Law or otherwise against any property. 
 “Loan
Documents” means, collectively, this Agreement, the Perfection Certificate, the Pledge Agreement, any note, or notes or guaranties executed by Borrower or any Guarantor in connection with the indebtedness governed by this Agreement, and any
other present or future agreement between Borrower and/or for the benefit of the Lenders and Agent in connection with this Agreement, all as amended, restated, or otherwise modified. 

  
 34 

 “Loan Party” means Borrower and each Guarantor. 

“Material Adverse Change” means (a) a material impairment in the perfection or priority of the Agent’s Lien in
the Collateral or in the value of such Collateral, taken as a whole; (b) a material adverse change in the business, operations, or condition (financial or otherwise) or prospects of Borrower, taken as a whole; or (c) a material impairment
of the prospect of repayment of any portion of the Obligations. 
 “Material Intellectual Property” means
Borrower’s Intellectual Property and license agreements that are material to the condition (financial or other), business or operations of Borrower, as determined by Agent. For purposes hereof, over the counter software that is commercially
available to the public shall not be deemed “material.” 
 “Maturity Date” means the Tranche One
Maturity Date or the Tranche Two Maturity Date, as applicable. 
 “[*]” means that certain Agreement dated [*] between
[*]. 
 “[*]” means the [*] under the [*]. 
 “[*]” means the [*] by Borrower to the [*] of the [*], the [*] by means of the [*] by Borrower to the [*] of the [*], and the [*] by the [*] of such [*]; provided, however, that
such [*] shall be subject to the following conditions, unless otherwise agreed in writing by the Required Lenders: (i) the [*] of the [*] from Borrower to the [*] shall not take place until the consummation of such transaction and until the
other conditions to the [*] have been satisfied; (ii) following the consummation of such [*], all required [*] from [*] that are [*] to the [*] and which are not used to [*] of such [*], shall be [*] to Borrower; (iii) other than with
respect to a [*], the [*], there shall be [*] (including, without limitation, any [*] in connection therewith); (iv) such transaction must have been approved in advance by the Board of Directors of Borrower; (v) prior to or simultaneously
with the consummation of such transaction, Borrower shall have [*] owned and in the name of Borrower all of [*] in connection therewith; and (vi) such transaction must have been consummated in accordance with current market terms. 

“[*]” means a wholly-owned direct Subsidiary of Borrower, formed for the sole purpose of [*], and subsequently [*];
provided, that, unless otherwise agreed to in writing by the Required Lenders: (i) there shall only be [*]; (ii) prior to the consummation of the [*] in accordance with the conditions thereto, such Subsidiary shall [*];
(iii) other than [*] upon consummation of the [*], no Borrower shall [*] to the [*], and (iv) such Subsidiary shall be [*] from Furiex and the other Borrowers. 
 “Obligations” means all of Borrower’s obligations to pay when due any debts, principal, interest, Lenders’ Expenses, the Prepayment Fee, the Final Payment, and other amounts
Borrower owes the Lenders now or later, under this Agreement or the other Loan Documents, including, without limitation, interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower
assigned to the Lenders and/or Agent, and the performance of Borrower’s duties under the Loan Documents. 

“OFAC” means the U.S. Department of Treasury Office of Foreign Assets Control. 

“OFAC Lists” means, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC
pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable
Executive Orders. 
 “Operating Documents” means, for any Person, (a) such Person’s formation
documents, as certified with the Secretary of State of such Person’s state of formation on a date that is no earlier than 30 days prior to the Closing Date, (b)(i) if such Person is a corporation, its bylaws in current form, (ii) if such
Person is a limited liability company, its limited liability company agreement (or similar agreement), or (iii) if such Person is a partnership, its partnership agreement (or similar agreement), and (c) any other organizational documents
of Borrower, in each case 

  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 35 

 
for clauses (a) through (c), together with all current amendments or modifications thereto and corporate, company, partner, member or shareholder resolutions associated therewith.

 “Ordinary Course of Business” means, in respect of any transaction involving any Loan Party, the ordinary
course of business of such Loan Party, as conducted by such Loan Party in accordance with past practices. 

“Payment/Advance Form” means that certain form attached hereto as Exhibit B. 

“Payment Date” means the first calendar day of each calendar month. 

“Perfection Certificate” has the meaning given it in Section 5.1. 

“Permits” means licenses, certificates, accreditations, product clearances or approvals, provider numbers or provider
authorizations, marketing authorizations, other authorizations, registrations, permits, consents and approvals required in connection with the conduct of Borrower’s or any Subsidiary’s business or to comply with any applicable Laws,
including, without limitation, drug listings and drug establishment registrations under 21 U.S.C. Section 510, registrations issued by DEA under 21 U.S.C. Section 823 (if applicable to any Product), and those issued by State governments
for the conduct of Borrower’s or any Subsidiary’s business. 
 “Permitted Indebtedness” means:

 (a) Borrower’s Indebtedness to the Lenders and Agent under this Agreement and the other Loan Documents; 

(b) Indebtedness existing on the Closing Date and described on Schedule 7.4; 

(c) unsecured Indebtedness to trade creditors incurred in the Ordinary Course of Business; 

(d) Indebtedness secured by Permitted Liens; 
 (e) Indebtedness of the [*] arising out of or related to the [*] (which may include a currency or interest rate hedge agreement that is not speculative in nature), and subject to the terms thereof; and

 (f) extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness
(a) through (d) above, provided, however, that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be. 

“Permitted Investments” means: 
 (a) Investments existing on the Closing Date and described on Schedule 7.7; 

(b) Investments consisting of Cash Equivalents; and 
 (c) Investments in Subsidiaries that exist as of the Closing Date and are Borrowers or that are otherwise created in accordance with Section 6.9 and subject to the terms thereof. 

“Permitted IP Dispositions” has the meaning given it in Section 7.1. 

“Permitted Liens” means: 
 (a) Liens existing on the Closing Date and shown on the Perfection Certificate or arising under this Agreement and the other Loan Documents; 

  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 36 

 (b) Liens for taxes, fees, assessments or other government charges or levies, either not
delinquent or being contested in good faith and for which Borrower maintains adequate reserves on its Books, provided, however, that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended ,
and the Treasury Regulations adopted thereunder; 
 (c) purchase money Liens (i) on Equipment acquired or held by Borrower
incurred for financing the acquisition of the Equipment securing no more than Two Hundred Fifty Thousand Dollars ($250,000) in the aggregate amount outstanding, or (ii) existing on Equipment when acquired, if the Lien is confined to the
property and improvements and the proceeds of the Equipment; 
 (d) statutory Liens securing claims or demands of materialmen,
mechanics, carriers, warehousemen, landlords and other Persons imposed without action of such parties, provided, however, that they have no priority over any of Agent’s Lien and the aggregate amount of such Liens does not any time exceed
Fifty Thousand Dollars ($50,000); 
 (e) leases or subleases of real property granted in the Ordinary Course of Business, and
leases, subleases, non-exclusive licenses or sublicenses of property (other than real property or Intellectual Property) granted in the Ordinary Course of Business, if the leases, subleases, licenses and sublicenses do not prohibit granting
Agent a security interest; 
 (f) banker’s liens, rights of setoff and Liens in favor of financial institutions incurred
made in the Ordinary Course of Business arising in connection with Borrower’s deposit accounts or securities accounts held at such institutions to secure payment of fees and similar costs and expenses subject to Borrower’s compliance with
Section 6.6(b) hereof; 
 (g) Liens to secure payment of workers’ compensation, employment insurance, old-age
pensions, social security and other like obligations incurred in the Ordinary Course of Business (other than Liens imposed by ERISA); 
 (h) Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default under Section 8.5 or 8.7; 

(i) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and similar charges or encumbrances
affecting real property not constituting a Material Adverse Change; 
 (j) non-exclusive licenses of Intellectual Property
granted to third parties in the Ordinary Course of Business and/or Permitted IP Dispositions; and 
 (k) Liens incurred in the
extension, renewal or refinancing of the indebtedness secured by Liens described in (a) and (c) above, but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal
amount of the Indebtedness may not increase. 
 “Person” means any individual, sole proprietorship,
partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

“PPD” means PPD Development, LP, a Texas limited partnership. 

“Prepayment Fee” means with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by
mandatory or voluntary prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to: 

(a) for a prepayment made on or after the Funding Date for such Term Loan through and including the date which is twelve (12) months
after such Funding Date, four percent (4.0%) multiplied by the original Term Loan Commitments; 

  
 37 

 (b) for a prepayment made after the date which is twelve (12) months after the Funding
Date for such Term Loan through and including the date which is twenty-four (24) months after such Funding Date, three percent (3.0%) multiplied by the original Term Loan Commitments for such Term Loan so prepaid; and 

(c) for a prepayment made after the date which is twenty-four (24) months after the Funding Date for such Term Loan through and
including the date which is thirty-six (36) months after such Funding Date, one percent (1.0%) multiplied by the original Term Loan Commitments for such Term Loan so prepaid. 

“Pro Rata Share” means, as determined by Agent, with respect to each Lender, a percentage (expressed as a decimal,
rounded to the ninth decimal place) determined by dividing the amount of Term Loans held by such Lender by the aggregate amount of all outstanding Term Loans. 
 “Products” means the Development Compounds and/or Sale Compounds. 

“Registered Organization” means any “registered organization” as defined in the Code, with such additions to
such term as may hereafter be made. 
 “Required Lenders” means Lenders having (a) more than 60% of the
Term Loan Commitments of all Lenders, or (b) if such Term Loan Commitments have expired or been terminated, more than 60% of the aggregate outstanding principal amount of the Term Loans; provided, however, that so long as a party that is
a Lender hereunder on the Closing Date does not assign any portion of its Term Loan Commitment or Term Loan, the term “Required Lenders” shall include such Lender. For purposes of this definition only, a Lender shall be deemed to
include itself, and any Lender that is an Affiliate or Approved Fund of such Lender. 
 “Required Permit” means
a Permit (a) issued or required under Laws applicable to the business of Borrower or any of its Subsidiaries or necessary in the manufacturing, importing, exporting, possession, ownership, warehousing, marketing, promoting, sale, labeling,
furnishing, distribution or delivery of goods or services under Laws applicable to the business of Borrower or any of its Subsidiaries or any Drug Application (including without limitation, at any point in time, all licenses, approvals and permits
issued by the FDA or any other applicable Governmental Authority necessary for the testing of any Development Compound or the manufacture, marketing or sale of any Sale Compound by any applicable Borrower(s) as such activities are being conducted by
such Borrower with respect to such Product at such time), and (b) issued by any Person from which Borrower or any of their Subsidiaries have received an accreditation. 
 “Requirement of Law” means as to any Person, the organizational or governing documents of such Person, and any Law (statutory or common), treaty, rule or regulation or determination of an
arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject. 

“Reserve Percentage” means, on any day, for any Lender, the maximum percentage prescribed by the Board of Governors of
the Federal Reserve System (or any successor Governmental Authority) for determining the reserve requirements (including any basic, supplemental, marginal, or emergency reserves) that are in effect on such date with respect to eurocurrency funding
(currently referred to as “eurocurrency liabilities”) of that Lender, but so long as such Lender is not required or directed under applicable regulations to maintain such reserves, the Reserve Percentage shall be zero. 

“Responsible Officer” means any of the Chairman, President, Chief Medical Officer or Chief Financial Officer of
Borrower. 
 “Sale Compound” means any therapeutic compound approved for marketing (“Approved Drug”)
that is manufactured, marketed or sold by any Borrower or any of its Subsidiaries, it being acknowledged and understood that as of the Closing Date, neither Borrower nor any of its Subsidiaries manufactures and sells Approved Drugs; provided,
in the event Borrower or its Subsidiaries engages in the manufacture or sale of Approved Drugs subsequent to the Closing Date and Borrower fails to comply with the obligations under Section 6.2(d) to give notice

  
 38 

 
to Agent and update Schedule 5.11 prior to manufacturing or selling any new Approved Drug, any such improperly undisclosed Approved Drug shall be deemed to be included in this definition.

 “Sale Inventory” means the inventory of Sale Compounds manufactured and held for sale by any Borrower or any
of its Subsidiaries, including without limitation such inventory of Sale Compounds as is temporarily out of Borrower’s custody or possession or in transit and including any returned Sale Compounds inventory. 

“Secured Promissory Note” has the meaning given it in Section 2.7. 

“Secured Promissory Note Record” means a record maintained by each Lender with respect to the outstanding Obligations
and credits made thereto. 
 “Securities Account” means any “securities account”, as defined in the
Code, with such additions to such term as may hereafter be made. 
 “Subject Intellectual Property” has the
meaning given it in Section 2.5(d). 
 “Subsidiary” means, with respect to any Person, any Person of which
more than 50.0% of the voting stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or one or more of Affiliates of such Person. 

“[*]” means, either individually or collectively as the context may require, [*], a Delaware corporation and [*], a company
organized and existing under the laws of [*]. 
 “Term Loan” or “Term Loans” has the meaning
given it in Section 2.2(a). 
 “Term Loan Commitment” means, for any Lender, the obligation of such Lender
to make a Term Loan, up to the principal amount shown on Schedule 1. “Term Loan Commitments” means the aggregate amount of such commitments of all Lenders. 

“Tranche One Maturity Date” means August 1, 2015, for the Tranche One Term Loan. 

“Tranche Two Eligibility Date” means the date on which Agent determines that Borrower has closed the [*] and has
received [*] of at least [*] dollars ($[*]) in connection therewith, which date must be prior to the Draw Period Termination Date. 
 “Tranche Two Maturity Date” means, if the Tranche Two Term Loan is advanced (i) on or prior to December 31, 2011, then the date that is thirty-six (36) months after the
Amortization Date of such Tranche Two Term Loan or (ii) after December 31, 2011, then the date that is thirty-three (33) months after the Amortization Date of such Tranche Two Term Loan. 

“Transfer” has the meaning given it in Section 7.1. 

[SIGNATURES APPEAR ON FOLLOWING PAGE(S)] 
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 39 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as
of the Closing Date. 
  

			
	BORROWER:
	
	FURIEX PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Marshall H. Woodworth

	Name:	 	Marshall H. Woodworth
	Title:	 	Chief Financial Officer
	
	APBI HOLDINGS, LLC
		
	By:	 	 /s/ Marshall H. Woodworth

	Name:	 	Marshall H. Woodworth
	Title:	 	Chief Financial Officer
	
	DEVELOPMENT PARTNERS, LLC
		
	By:	 	 /s/ Marshall H. Woodworth

	Name:	 	Marshall H. Woodworth
	Title:	 	Chief Financial Officer
	
	GENUPRO, INC.
		
	By:	 	 /s/ Marshall H. Woodworth

	Name:	 	Marshall H. Woodworth
	Title:	 	Chief Financial Officer

 
			
	AGENT:
	
	MIDCAP FUNDING III, LLC,
	as Agent for Lenders
		
	By:	 	 /s/ Josh Groman

	Name:	 	Josh Groman
	Title:	 	Managing Director

 
			
	LENDERS:
	
	MIDCAP FUNDING III, LLC,
	as a Lender
		
	By:	 	 /s/ Josh Groman

	Name:	 	Josh Groman
	Title:	 	Managing Director
	
	Address for notices:
	
	 MidCap Funding III, LLC
 7255 Woodmont Avenue, Suite 200
 Bethesda, Maryland 20814

Attention: Portfolio Management- Life Sciences

Fax: (301) 941-1450
 E-Mail:
Lviera@midcapfinancial.com

	
	with a copy to:
	
	 Midcap Financial, LLC
 7255 Woodmont Avenue, Suite 200
 Bethesda, Maryland 20814

Attention: General Counsel
 Fax: (301)
941-1450
 E-Mail: Rgoodridge@midcapfinancial.com

 
			
	SILICON VALLEY BANK,
	as a Lender
		
	By:	 	 /s/ Chris J. Stoecker

	Name:	 	Chris J. Stoecker
	Title:	 	VP
	
	Address for notices:
	
	 Silicon Valley Bank

3005 Carrington Mill Boulevard, Suite 530
Morrisville, North Carolina 27560

 Attention: Chris Stoecker, Relationship Manager
Fax: (919) 461-3908

 EXHIBITS AND SCHEDULES 

 

			
	EXHIBITS
		
	 Exhibit A
	  	Collateral
	 Exhibit B
	  	Loan Payment / Advance Request Form
	 Exhibit C
	  	Compliance Certificate
	
	SCHEDULES
		
	 Schedule 1
	  	Lenders and Commitments
	 Schedule 5.1
	  	Organizational Information
	 Schedule 5.2
	  	Collateral Disclosures
	 Schedule 5.3
	  	Litigation
	 Schedule 5.11
	  	Products and Required Permits
	 Schedule 6.12
	  	Post Closing Obligations
	 Schedule 7.4
	  	Indebtedness
	 Schedule 7.7
	  	Investments

  
 2 

 EXHIBIT A 

COLLATERAL 
 The Collateral consists of all assets of Borrower, including all of Borrower’s right, title and interest in and to the following personal property: 

(a) all goods, Accounts (including health-care insurance receivables), Equipment, Inventory, contract rights or rights to payment of
money, leases, license agreements, franchise agreements, General Intangibles, commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, investment
accounts, commodity accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting
obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and 
 (b) all Borrower’s
Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance
proceeds of any or all of the foregoing. 
 Notwithstanding the foregoing, the Collateral shall not include any Intellectual
Property of any Loan Party, whether now owned or hereafter acquired, except to the extent that it is necessary under applicable law to have a Lien and security interest in any such Intellectual Property in order to have a perfected Lien and security
interest in and to IP Proceeds (defined below), and for the avoidance of any doubt, the Collateral shall include, and Agent shall have a Lien and security interest in, (i) all IP Proceeds, and (ii) all payments with respect to IP Proceeds
that are received after the commencement of a bankruptcy or insolvency proceeding. The term “IP Proceeds” means, collectively, all cash, Accounts, license and royalty fees, claims, products, awards, judgments, insurance claims,
and other revenues, proceeds or income, arising out of, derived from or relating to any Intellectual Property of any Loan Party, and any claims for damage by way of any past, present or future infringement of any Intellectual Property of any Loan
Party (including, without limitation), all cash, royalty fees, other proceeds, Accounts and General Intangibles that consist of rights of payment to or on behalf of a Loan Party and the proceeds from the sale, licensing or other disposition of all
or any part of, or rights in, any Intellectual Property by or on behalf of a Loan Party). 
 Notwithstanding the foregoing, the
Collateral shall not include any rights of the Borrower under the [*], but prior to the consummation of the [*], shall include the [*] License Proceeds. The term “[*] License Proceeds” means, collectively, all IP Proceeds arising
out of, derived from or relating to the [*] or any associated Intellectual Property. 
 Agent and Lenders further acknowledge
that the Collateral shall not include more than 65% of the voting securities of any Subsidiary that is not organized under the laws of the United States or any of its states if such pledge would cause a material increase in the Borrower’s
federal income tax liability. 
 Pursuant to the terms of a certain negative pledge arrangement with Agent and Lenders,
Borrower has agreed not to encumber any of its Intellectual Property without Agent’s and Lenders’ prior written consent; provided, however, Borrower may enter into the [*], so long as it has satisfied the conditions for such
transaction outlined in the defined term “[*].” 
  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  
 3 

 EXHIBIT B 

LOAN PAYMENT/ADVANCE REQUEST FORM 
 DEADLINE IS NOON E.S.T. 
  

							
		 		 		 	Date:                     , 201    

 LOAN PAYMENT: 
 From Account
#                                         
                                   To Account 

#                         
                                         
                   

    (Deposit Account #)
                                         
                                   (Loan Account #) 

Principal
$                                         
                                        and/or
Interest 

$                         
                                         
                                        

Authorized Signature:
                                        
            Phone Number:
                                         
                                

Print Name/Title:
                                       

LOAN ADVANCE: 
 Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire. 

From Account
#                                         
                               To Account 

#                         
                                         
               
     (Loan Account
#)
                                         
                       (Deposit Account #) 
 Amount of Advance
$                                         
          
 All Borrower’s representations and warranties in the Loan and
Security Agreement are true, correct and complete in all material respects on the 
 date of the request for an advance;
provided, however, that such materiality qualifier shall not be applicable to any representations and warranties 
 that
already are qualified or modified by materiality in the text thereof; and provided, further, that those representations and warranties expressly 
 referring to a specific date shall be true, accurate and complete in all material respects as of such date: 
 Authorized
Signature:                                      
      Phone Number:
                                         
                                

Print Name/Title:
                                       

OUTGOING WIRE REQUEST: 

Complete only if all or a portion of funds from the loan advance above is to be wired. 

Beneficiary Name:
                                         
                                         
                                         
                                         

 Amount of Wire:
$                                         
                                         
               
 Beneficiary Lender:
                                         
            
 Account Number:
                                         
                                         
               
 City and State:
                                         
        
 Beneficiary Lender Transit (ABA) #:
                                        
        Beneficiary Lender Code (Swift, Sort, Chip, etc.):              

(For International Wire Only) 

 Intermediary Lender:
                                        
                 Transit (ABA) #:
                                         
                                        

For Further Credit to:
                                         
                                         
                                         
                                         

 Special Instruction:
                                         
                                         
                                         
                                         
     
 By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be
processed in accordance with and subject to the 
 terms and conditions set forth in the agreements(s) covering funds
transfer service(s), which agreements(s) were previously received and 
 executed by me. 

Authorized Signature:
                                         
                            2nd Signature (if required): 
                                  
                                         
   
 Print Name/Title:
                                         
                                         
              Print Name/Title: 

                         
                                         
                   
 Telephone #:
                                        
                         Telephone #:
                                         
                                         
   

  
 2 

 EXHIBIT C 

COMPLIANCE CERTIFICATE 
  

					
	TO:	  	MidCap Funding III, LLC, as Agent	  	
	FROM:	  		  	
	DATE:	  	                    , 201  	  	

 The undersigned authorized officer of
                                 (“Borrower”) certifies that under the
terms and conditions of the Loan and Security Agreement between Borrower, Agent and the Lenders (the “Agreement”): 
 (1) Borrower is in complete compliance with all required covenants for the month ending
                    , 201  , except as noted below; 
 (2) there are no Events of Default; 
 (3) all representations and warranties
in the Agreement are true and correct in all material respects on this date except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or
modified by materiality in the text thereof; and provided, further, that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; 

(4) Borrower, and each of its Subsidiaries, has timely filed all required tax returns and reports, and Borrower has timely paid all
foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except as otherwise permitted pursuant to the terms of Section 5.8 of the Agreement; and 

(5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits
of which Borrower has not previously provided written notification to Agent. 
 Attached are the required documents supporting
the certifications set forth in this Compliance Certificate. The undersigned certifies, in his/her capacity as an officer of the Borrower, that these are prepared in accordance with GAAP consistently applied from one period to the next except as
explained in an accompanying letter or footnotes. The undersigned acknowledges, in his/her capacity as an officer of Borrower, that no borrowings may be requested at any time or date of determination that Borrower is not in compliance with any of
the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement. 

Please indicate compliance status by circling Yes/No under “Complies” column. 

 

					
	 Reporting Covenant
	  	 Required
	  	 Complies

	Monthly Financial Statements	  	Monthly within 45 days	  	Yes            No
			
	Audited Financial Statements	  	Annually within 150 days after FYE	  	Yes            No
			
	Board Approved Projections	  	Annually within 90 days after FYE	  	Yes            No
			
	Compliance Certificate	  	Monthly within 45 days	  	Yes            No

 The following are the exceptions with respect to the certification above: (If no exceptions
exist, state “No exceptions to note.”) 
  
  

 
  
  

 
  

									
	[NAME OF BORROWER]	 		 	AGENT USE ONLY
					
		 		 		 	Received by:	 	  

	By:	 	  
	 		 	AUTHORIZED SIGNER
	Name:	 	  
	 		 	Date:	 	  

	Title:	 	  
	 		 		 	
		 		 		 	Verified:	 	  

		 		 		 	AUTHORIZED SIGNER
		 		 		 	Date:	 	  

				
		 		 		 	Compliance
Status:                Yes        No

 SCHEDULE 1 

LENDERS AND COMMITMENTS 
  

									
	 Lender
	  	Term Loan
Commitment	 	  	Commitment
Percentage	 
	 MidCap Funding III, LLC
	  	$	7,500,000	  	  	 	50	% 
	 Silicon Valley Bank
	  	$	7,500,000	  	  	 	50	% 
		  	  
	  
	 	  	  
	  
	 
	 TOTAL
	  	$	15,000,000	  	  	 	100	% 
		  	  
	  
	 	  	  
	  
	 

 SCHEDULE 5.1 

ORGANIZATIONAL INFORMATION 
  

											
	 Legal Name of Borrower
	 	 Type of Legal Entity
	 	 State of Organization
	 	Organizational
Identification
Number	 	 Tax
Identification
Number
	 	 Principal Place of Business

	Furiex Pharmaceuticals, Inc	 	Corporation	 	Delaware	 	4744208	 	27-1197863	 	3900 Paramount Parkway, Suite 150 Morrisville, NC 27560
						
	APBI Holdings, LLC	 	Limited Liability Company	 	North Carolina	 	0703248	 	N/A	 	 3900 Paramount Parkway, Suite 150
 Morrisville, NC 27560

						
	Development Partners, LLC	 	Limited Liability Company	 	Delaware	 	3728473	 	20-0417496	 	 3900 Paramount Parkway, Suite 150
 Morrisville, NC 27560

						
	GenuPro, Inc	 	Corporation	 	North Carolina	 	0459382	 	56-2085866	 	 3900 Paramount Parkway, Suite 150
 Morrisville, NC 27560

 SCHEDULE 5.2(a) 

COLLATERAL ACCOUNTS 
 Furiex Pharmaceuticals, Inc. maintains the following Deposit Accounts and Securities Accounts: 
  

					
	 Bank Name
	  	Account Number	 	Branch Address
	[*]	  	[*]	 	[*]

  

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

 SCHEDULE 5.2(d) 

INTELLECTUAL PROPERTY AND LICENSE AGREEMENTS 

 SCHEDULE 5.2(e) 

LOCATION OF COLLATERAL 
 LOCATION OF COLLATERAL 
 3900 Paramount Parkway, Suite 150 

Morrisville, NC 27560 
 929 North Front Street

 Wilmington, NC 28401 
 980 Harvest
Drive, Suite 130 
 Blue Bell, PA 19422 

7551 Metro Center Drive, Suite 300 
 Austin, TX
78744 
 2244 Dabmeu Road 
 Richmond,
VA 23230 
 3202 Tower Oaks Boulevard, Suite 300 
 Rockville, MD 20852 

 SCHEDULE 5.3 

LITIGATION 
 None.

 SCHEDULE 5.11 

PRODUCTS AND REQUIRED PERMITS 
 1. PRODUCTS 
 a. PPD-10558 

b. JNJ-32729463 

c. JNJ-27018966 
 2. REQUIRED
PERMITS 
 a. The following regulatory applications for performing human clinical trials: 

 

	 	(i)	PPD10558 - IND No. 76,475 

  

	 	(ii)	JNJ-32729463 - IND No. 102,844 (Tablets), IND No. 107,488 (IV); CTA No. 61-3910-4036748 (Germany), CTA No. 73/UR/CEBK/01/11 (Poland), Protocol
No. 32792463CAP2001 (Hungary), MoH Reference No. 035-11 (Peru); MoH Reference No. EC267853/11 (Chile). 

  

	 	(iii)	JNJ-27018966 - IND No. 79,214 

 SCHEDULE 6.12 

POST CLOSING OBLIGATIONS 
 Borrowers shall satisfy and complete each of the following obligations, or provide Agent each of the items listed below, as applicable, on or before the date indicated below, all to the satisfaction of
Agent in its sole and absolute discretion: 
 (a) By not later than thirty (30) days after the Closing Date, Borrower shall
cause each of its deposit and/or securities accounts located at Branch Banking & Trust Company to be closed and all funds or other items on deposit in such deposit and/or securities accounts to be deposited into a Collateral Account which
is subject to a Control Agreement in favor of Agent. 
 (b) By not later than sixty (60) days after the Closing Date,
Borrower shall deliver a fully executed and complete Control Agreement executed by all parties thereto with respect to Borrower’s account numbered [*] located at Merrill Lynch and set forth on Schedule 5.2(a)(the “ML SACA”). Until
such time as Borrower obtains the fully-executed ML SACA and for ninety-one (91) days thereafter, Borrower shall maintain cash and Cash Equivalents of not less than ten million dollars ($10,000,000.00) in one of the SVB deposit or securities
accounts subject to a Control Agreement. 
 Borrower’s failure to complete and satisfy any of the above obligations on or
before the date indicated above, or Borrower’s failure to deliver any of the above listed items on or before the date indicated above, shall constitute an immediate an automatic Event of Default. 

 

	[*]	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

 SCHEDULE 7.4 

INDEBTEDNESS AS OF THE CLOSING DATE 
 None. 

 SCHEDULE 7.7 

INVESTMENTS AS OF THE CLOSING DATE 
 See the Collateral Accounts listed on Schedule 5.2(a) hereto. 
 Furiex Pharmaceuticals, Inc. has
the following subsidiaries: 
  

	 	•	 	 100% membership interest in APBI Holdings, LLC, a North Carolina limited liability company 

 

	 	•	 	 100% membership interest in Development Partners, LLC, a Delaware limited liability company 

 

	 	•	 	 500,000 shares of common stock of GenuPro, Inc., a North Carolina corporation representing 100% of its issued and outstanding shares

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]